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Periodontitis is an inflammatory disease induced by complex interactions 
between the host immune system and pathogens that affect the integrity of teeth-
supporting tissues. To prevent disease progression and thus preserve the alveolar 
bone structure, simultaneous anti-inflammatory and osteogenic intervention is 
essential. Hence, simvastatin (SIM) and a glycogen synthase kinase 3 beta 
inhibitor (BIO) were selected as anti-inflammatory and osteogenic agents.  
First, SIM is a HMG-CoA reductase inhibitor widely prescribed for 
hypercholesterolemia. It has been reported to ameliorate inflammation and 
promote osteogenesis.  Its clinical applications on these potential secondary 
indications, however, have been hampered by its lack of osteotropicity and poor 
water solubility.  To address this challenge, we proposed to design and evaluate 
the therapeutic efficacy of a novel simvastatin prodrug with better water solubility 
and bone affinity. The prodrug (SIM-PPi) was synthesized by directly conjugating 
a SIM trimer to a pyrophosphate (PPi).  It was characterized and evaluated in vitro 
for its water solubility, osteotropicity, toxicity, anti-inflammatory, and osteoinductive 
properties.  It was then tested for anti-inflammatory and osteoinductive properties 
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in vivo by three weekly injections into gingiva of a ligature-induced experimental 
periodontitis rat model.  In vitro studies showed that SIM-PPi has greatly improved 
water-solubility of SIM and shows strong binding to hydroxyapatite (HA).  In 
macrophage culture, SIM-PPi inhibited LPS-induced pro-inflammatory cytokines 
(IL-1β, IL-6).  In osteoblast culture, it was found to significantly increase alkaline 
phosphatase (ALP) activity with accelerated mineral deposition, confirming the 
osteogenic potential of SIM-PPi.  When tested in vivo on an experimental 
periodontal bone-loss model, SIM-PPi exhibited a superior prophylactic effect 
compared to dose equivalent SIM in reducing inflammatory cells and in preserving 
the alveolar bone structure, as shown in the histological and micro-CT data.  
Second, a glycogen synthase kinase 3 beta inhibitor (BIO) is a potent 
inflammation modulator and osteogenic agent. However, its lack of osteotropicity, 
poor water solubility, and potential long-term side effects have hampered its clinical 
applications. To address these limitations, pyrophosphorylated Pluronic F127 was 
synthesized to prepare a novel, injectable and thermosensitive hydrogel (PF127) 
that could effectively release BIO to exert its therapeutic effects locally. Comparing 
to F127 hydrogel, PF127 hydrogels exhibited strong binding to hydroxyapatite (HA) 
discs as a function of PPi content. Additionally, BIO’s solubility in PF127 solution 
compared to F127 was greatly improved and proportionally to the polymer 
concentration. When tested in vivo on an experimental periodontal bone-loss rat 
model, PF127-BIO hydrogel exhibited a superior prophylactic effect in preserving 
alveolar bone structure and preventing periodontal inflammation, as shown by the 
micro-CT and histological data, respectively.  
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Altogether, these two delivery strategies (SIM-PPi prodrug and PF127 
hydrogel) with excellent bone binding may have the potential to be further 
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 1.1 Periodontal diseases: definitions and classifications 
Periodontal or gum diseases are a group of inflammatory disorders that 
compromise the supporting tissues of teeth and share common clinical 
manifestations. Based on the progressive nature of periodontal diseases, they can 
be divided into two main stages. First, gingivitis which is an early and non-
destructive inflammatory disease that occurs when dental plaque accumulates 
around teeth and affects soft tissues surrounding the teeth. It causes gum swelling 
with a tendency to bleed upon slight provocation(1).  
 
Second, periodontitis, the focus of this dissertation, is the destructive stage 
of periodontal disease that is associated with bleeding upon probing, increased 
probing depth, and may cause gingival recession. It can present in a localized or 
generalized form and characterize by periodontal inflammation of soft and hard 
tissues leading to periodontal attachment and alveolar bone loss(2). Periodontitis 
can be classified based on its progression into chronic and aggressive. The chronic 
form is most prevalent in adults and characterized by slow and progressive 
attachment and bone loss, while aggressive form results in rapid and severe 
attachment loss and bone destruction(3).  
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The disease afflicts  45.9 % of adults in the United States, confirming the 
high burden of periodontitis(4). Men are more likely to have gum disease than 
women, and teenagers rarely develop periodontitis, but they can develop gingivitis. 
Furthermore, the harmful health impact of periodontitis is not only limited to the 
local tissue destruction and alveolar bone resorption, but it may also affect 
systemic health by increasing the incidence risk of systemic inflammatory 
diseases, atherosclerosis, and cancer(5).  
 1.2 Risk factors  
 
       1.2.1 Smoking 
 
It has been clinically established and demonstrated that a positive 
correlation between cigarette smoking and a higher risk for periodontal disease 
and alveolar bone loss is clear(6). Nicotine is one of the most pharmacologically 
active compounds in cigarette smoke. It has been shown to promote collagen 
breakdown and to inhibit gingival fibroblast growth and production of fibronectin 
and collagen in vitro, which are vital components to a healthy periodontium(7). 
Furthermore, it has been shown that when periodontal cells exposed to nicotine, 
the growth and protein content were decreased. Also, damaged cell membranes 
and atypical shapes were observed(8). Nicotine also has been evidenced to 
stimulate osteoclast differentiation and the resorption of calcium phosphate which 
may illustrate the severity of alveolar bone loss and refractory disease incidence 
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in smokers(9). Nicotine has also been shown to delay apoptosis which would allow 
for osteoclasts to persist the resorptive process(10). 
 
        1.2.2 Diabetes 
 
Both type 1 and type 2 diabetes mellitus has been confirmed as a major risk 
factor for periodontal diseases(11–13). The risk of periodontitis is increased by 
approximately threefold in diabetics compared with non-diabetic individuals, and 
higher risk with poor glycemic control(14). When glucose is elevated in saliva, 
harmful bacteria grow in saliva and combine with food to form a soft plaque. In a 
study of 350 diabetic children (6–18 years old) vs 350 non-diabetic controls, the 
proportion of periodontal disease was greater in the children with diabetes (>20% 
vs 8% of sites, respectively)(15). The mechanisms by which diabetes affects 
periodontal health are complicated and still not solely defined. It has been 
proposed that upregulated pro-inflammatory cytokines, the formation of advanced 
glycation end-products (AGEs), and reactive oxygen species (ROS) are 
mechanisms that affect periodontal tissues. It has been reported that the level of 
pro-inflammatory cytokines PGE2 and IL-1β is higher in GCF of diabetics when 
compared to non-diabetics(16). AGEs bind to their receptor (RAGE), which is 
overexpressed in diabetics(17), and stimulate pro-inflammatory cytokines(18,19) 
and also induce osteoblast apoptosis(20). As oxidative stress is increased in 




 1.3 Pathogenesis  
The disease initiates with gingivitis which is considered a significant risk 
factor for developing periodontitis, an irreversible immune reaction. It 
characterized by the loss of teeth-attached soft tissues and severe alveolar 
bone resorption which may lead to teeth loss.  It has been reported that 
gingivitis does not always develop into periodontitis, indicating that in addition 
to plaque accumulation, host susceptibility is necessary to develop 
periodontitis(5).  Once periodontitis is established, a pro-inflammatory cytokine 
cascade would initiate the destruction of soft and hard tissues.  It is well 
reported that pro-inflammatory cytokines secreted by monocytes, lymphocytes, 
and some resident fibroblasts are responsible for the disease progression(22).  
Interleukin-1β (IL-1β) is considered one of the most potent inducers of bone 
resorption and is reported to be elevated in inflamed gingival tissues and 
gingival crevicular fluid (GCF) promoting connective tissues destruction 
through inducing matrix metalloproteinases (MMPs)(22).  Subsequently, 
interleukin-6 (IL-6) is secreted in response to bone resorbing inducers including 
IL-1β(22). This inflammatory cascade promotes osteoclastogenesis by 
disrupting the balance between receptor activator of nuclear factor kappa-B 
ligand (RANKL) and its decoy receptor osteoprotegerin (OPG).  The RANKL 
will be overexpressed to interact with receptor activator of nuclear factor kappa-
B (RANK) receptor expressed on the osteoclast precursor cells, promoting 




 1.4 Conventional treatment    
       1.4.1 Mechanical therapy 
Scaling and root planing (SRP) is the non-surgically based therapy that is 
aimed at reducing the levels and proportions of periodontal pathogens and 
increasing the proportions of beneficial species(25). SRP is the nonsurgical-based 
therapy and performed to remove dental biofilm and calculus from periodontal 
pockets and smoothing the tooth root to eliminate bacterial toxins, thereby 
reducing the host inflammatory response. While scaling means the removal of 
plaque, calculus, and stains on the crown or root surface, root planing indicates 
the removal of cementum or surface dentin that is rough or contaminated with 
bacterial toxins. The beneficial outcomes following SRP therapy have been 
reported as decreases in the probing depth (PD) and increases in the clinical 
attachment level (CAL)(26). 
 
        1.4.2 Antimicrobial agents 
Due to the difficulty in adequately reducing bacteria using mechanical 
debridement alone, antibiotics such as tetracyclines, doxycycline, metronidazole, 
amoxicillin, ciprofloxacin, and azithromycin may be used as adjunctive 
therapy(27). Systemic administration has been shown to be effective as adjunctive 
therapy in the treatment of chronic and aggressive periodontitis(28). These agents 
accumulate in connective tissue, saliva, and gingival crevicular fluid. Local delivery 
is another route of administration using different delivery systems by which drug is 
placed into the periodontal pocket and sustainably released over time aiming at 
affecting periodontal pathogens at the site of injection.  
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      1.4.3 Host modulation agents 
Host modulation is another approach for treating periodontal disease. This 
therapy aims at affecting the host’s response to the bacterial challenge through 
ameliorating inflammation or inducing osteogenesis, thereby preventing the 
progression of the disease. 
 
        1.4.3.1 Non-steroidal anti-inflammatory agents (NSAIDs) 
 
NSAIDs have been used as adjunctive therapy to SRP therapy. They work 
by inhibiting cyclooxygenase (COX-1 and/or COX-2) and thus prostaglandin 
synthesis, including PGE2. Non-selective NSAIDs (i.e. COX-1 and COX-2 
inhibitors) that have been used in periodontal research include; aspirin, 
flurbiprofen, ibuprofen, naproxen, and piroxicam. Whereas, selective NSAIDs (i.e. 
COX-2 inhibitors) include; meloxicam, nimesulide, etodolac, and celecoxib. Long-
term use of NSAIDs was shown to reduce alveolar bone loss in patients with 
periodontitis(29). A review study on the effects of NSAIDs concluded that although 
some results were promising, no data from long-term, multicenter prospective 
clinical trials are available for determining whether these therapeutic effects can 
be retained on a long-term basis(30). Furthermore, chronic use of non-selective 





     1.4.3.2 Subantimicrobial dose doxycycline (SDD) 
 
SDD, known commercially as Periostat®, is a 20-mg capsule of doxycycline 
hyclate taken orally twice a day for a period of three to nine months. Due to this 
prolonged dosage scheduling, patient compliance and the cost are considered as 
disadvantages of this therapy. It is the first FDA approved systemic drug for host 
modulation as an adjunct to mechanical therapy in the treatment of 
periodontitis(31). Its clinical efficacy has been shown to be partially through its 
ability to inhibit collagenolytic matrix metalloproteinases (MMPs) in gingival tissues 
and fluid, specifically MMP-8 and MMP-13(32) Long-term periodontal treatment 
with SDD has proven to exert no antimicrobial effect on the periodontal microflora 
associated with chronic periodontitis(33). It has been shown that when SDD is 
used in addition to SRP in patients with chronic periodontitis, clinical parameters 
of periodontitis such as CAL and PDs were significantly improved compared to 
SRP therapy alone(34).  
 
       1.4.3.3 Bisphosphonates 
 
Bisphosphonates are a class of molecules known to chelate with calcium 
ions in the bone and considered as potent inhibitors of bone resorption. They 
have been effectively used in bone targeting and bone loss-related 
disorders such as osteoporosis and periodontal disease. Specifically, 
alendronate acts as a potent inhibitor of bone resorption and has been used 
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widely in periodontitis management. Several studies have shown that local 
application of alendronate to oral bone preserve or stimulate bone growth(35–43). 
However, the long-term clinical use of bisphosphonates has been associated with 
higher incident rates of osteonecrosis of the jaw (ONJ) and atypical fracture which 
limit their use(44,45).      
 
         1.4.3.4 Statins 
 
Statins are a class of anti-hyperlipidemic agents that have gained research 
interest in the treatment of periodontal disease. They act mainly through hepatic 
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibition, thereby affecting the 
metabolic pathway that produces cholesterol(46). Researchers have found that 
statins, such as simvastatin (SIM) and lovastatin, induce the expression of bone 
morphogenic protein-2 (BMP-2) leading to substantial osteogenic effects(47,48).  
Furthermore, SIM has been reported as a potent antimicrobial agent against both 
A. actinomycetemcomitans and P. gingivalis(49), and an anti-inflammatory agent 
that reduces the expression of cytokines such as IL-6, IL-8, and MCP-1, both in 
vitro and in vivo by inhibiting the activation of NF-κB that regulates the expression 
of diverse inflammatory cytokines(50,51).  Due to these unique therapeutic 
properties, statins have been considered as potential therapeutic candidates for 
periodontitis.  The translation of this therapeutic potential into clinical practice, 
however, has been largely hampered by the statins’ lack of tissue specificity, 




Systemic administration of SIM has been investigated for effects on 
periodontitis-associated alveolar bone loss and has exhibited a limited impact on 
periodontal bone due to its hepatotropicity resulting in very limited drug 
concentration at the skeletal tissues(52). However, local delivery of simvastatin as 
an adjunct to mechanical periodontal treatment (SRP) has been shown to improve 
bone regeneration in chronic(53,54) and aggressive periodontitis(55). Meta-
analysis has confirmed simvastatin as an effective adjunct to SRP for creating 
bone fill(56). Yet, SIM’s water solubility and osteotropicity remain challenging.  
 
 1.5 Local drug delivery systems for the treatment of periodontitis 
Even though mechanical management (SRP) removes plaque which 
contains microorganisms, its effectiveness is limited due to lack of accessibility to 
bacteria in deeper periodontal pockets. Surgical therapy may be useful but cannot 
be done in medically compromised individuals. Therefore, therapeutic agents are 
recommended as adjunctive therapy to prevent disease progression. These 
agents (antimicrobials and host modulators) mostly are administered systemically 
which exposes the body to large dose causing antibiotic resistance, adverse drug 
reaction, and side effects, making them less patient compliant(57,58). Additionally, 
high concentration of the drug in GCF cannot be achieved when given systemically 
as drug distributes during circulation to other organs of the body(59). Alternatively, 
local drug delivery in the form of intra-pocket administration proven to be more 
advantageous than systemic administration(58,60). When antibiotics and other 
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therapeutic agents are delivered locally, a high concentration of drug inside 
periodontal pockets can be attained with reduced systemic distribution, thereby 
minimizing side effects, and high potential acceptability. However, rapid drug 
clearance from periodontal pockets requires repeated applications which could 
reduce patient compliance and be indicative of a low clinical translation potential. 
Hence, local drug delivery systems have been developed to overcome all such 
limitations. These systems were aimed at achieving sustained/controlled drug 
release, maintaining therapeutic concentrations at the periodontal site over a 
period of time, thereby reducing dosing frequency, and improving patient 
adherence. In this section, the main local drug delivery systems developed for drug 
administration to the periodontal pocket and their effectiveness in the periodontal 
therapy will be discussed. They include; fibers, films, gels, microparticles, 
nanoparticles, and others.   
 1.5.1 Fibers 
 
Fiber-based drug delivery systems are described as slender, elongated 
thread-like polymeric structures with the ability to enhance drug solubility and the 
sustainable release of therapeutic agents at the target site. They are placed into 
the periodontal pocket and secured with periodontal dressing to ensure a 
sustained release of the entrapped drug into the pocket. Several polymers have 
been utilized such as poly(e-caprolactone) (PCL), polyurethane, polypropylene, 
cellulose acetate propionate, ethyl vinyl acetate (EVA), alginate, collagen, nylon, 
and chitosan. There are two types of fibers that have been used in periodontal 
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drug delivery; hollow and monolithic fibers. Hollow fibers are comprised of drug 
reservoirs loaded with drug molecules. These fibers release therapeutic agent by 
simple diffusion through the reservoir wall(61). When these hollow fibers of 
cellulose acetate filled with tetracycline are locally delivered into periodontal 
pockets, a dramatic reduction in the periodontal microflora and clinical signs of 
disease were shown by these fibers loaded with less than 1/1000 tetracycline dose 
that would have been used for systemic therapy(62). However, due to simple 
diffusion, the release of the tetracycline from the cellulose acetate hollow fibers 
was very rapid with approximately 95% of the drug released in the first two hours. 
Hence, an effective drug concentration for long periods with a single application 
could not be obtained. In another study, when these fibers containing 20% (v/v) 
chlorhexidine were delivered into periodontal pockets, a prompt and significant 
reduction in signs and symptoms of periodontitis was exhibited(63).  
 
To improve fiber delivery efficiency, monolithic fibers were developed by 
loading drug into the molten polymers, spinning it at high temperature followed by 
rapid cooling(64). Several in vitro and in vivo studies showed that these fibers were 
effective in slowly releasing the encapsulated drug. In one study, EVA monolithic 
fibers loaded with 25% tetracycline hydrochloride were delivered locally into the 
periodontal pocket of 10 patients as an adjunct to mechanical therapy and oral 
hygiene. The fibers reduced the total count of pocket microflora to a level near the 
limit of dark field microscopy, reduced bleeding on probing, decreased pocket 
depth probing, and increased attachment levels(65). Furthermore, chitosan-based 
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fiber containing tetracycline treatment as an adjunct to mechanical periodontal 
therapy in moderate to advanced periodontitis patients was effective in regard to 
probing pocket depth reduction and bleeding on probing, while fiber treatment only 
did not exhibit any beneficial effect on gain of clinical attachment level(66). 
Periodontal Plus AB™ (Advanced Biotech Products, Chennai, India) is 
biodegradable tetracycline-impregnated fibrillar collagen that contains 25 mg pure 
fibrillar collagen with approximately 2 mg of tetracycline hydrochloride. It is 
commercially available and has been introduced for the treatment of gingival and 
periodontal diseases(67). Moreover, ciprofloxacin and diclofenac sodium have 
been formulated into fibers comprised of alginate and glycerol crosslinked with 
barium cations, and resulted in growth inhibition of E. coli, E. faecalis, and S. 
mutans over 10 days in vitro(68). Also, gentamicin sulfate was incorporated in 
gravity-spun polycaprolactone (PCL) fibers that can be used for periodontal 
disease, and growth of Staphylococcus epidermidis was suppressed up to 2 weeks 
in vitro(69). Another nylon-based fiber loaded with amoxicillin trihydrate was 
prepared for periodontal infections and found to be very effective in vitro in the 
controlled delivery of amoxicillin and can be an alternative to systemic 
administration(70).  Nanofibers also have been recently studied, as delivery 
systems, for local application due to their special structure, which resembles the 
extracellular matrix. Several antibiotics include tetracycline hydrochloride(71), 
doxycycline(72), amoxicillin(73), metronidazole(73,74), and metronidazole 
benzoate(75) have been incorporated into nanofibers. To conclude, though the 
clinical efficacy of these fibers demonstrated by well conducted and well-controlled 
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studies, their placement has been challenging as patients experience discomfort 
during fiber placement and various degrees of gingival redness were observed at 
fiber removal. The intricacies of winding a fiber into place, and then the removal of 
it after several days may limit its wide acceptance in clinical settings(76). 
 
     1.5.2 Films  
Films or chips are implantable polymeric matrix drug delivery devices, 
where drug molecules are distributed throughout the polymer. Polymeric films have 
been made for the sustained release of therapeutic agents at the site of action. 
The ease of application with minimal pain, high drug loading, and controlled size 
of the films make them an ideal device to be used in periodontal pockets for drug 
delivery. The thickness of the film should not exceed 400 μm and should possess 
adhesive property to ensure stability during oral hygiene practice.  Drug release 
occurs by diffusion and/or matrix dissolution or erosion. The release mechanism 
depends on the type of polymer used to make the chip. When water-insoluble non-
degradable polymers are used to prepare films, drug release is mediated through 
diffusion alone. Those prepared with soluble or biodegradable polymers release 
drug by diffusion and matrix erosion or dissolution mechanisms(77).  
Non-biodegradable ethyl cellulose has been used to prepare films for the 
delivery of chlorhexidine gluconate/diacetate(78), metronidazole(79–81), 
tetracycline(82,83), and minocycline(84) and showed greater improvements in the 
incidence of bleeding on probing, probing depths and attachment levels compared 
to traditional periodontal therapy. It was noticed that the use of chloroform as the 
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casting solvent significantly slowed the release rate compared to ethanol. 
However, when polyethylene glycol was added into the films, the release rate of 
the drugs increased(85). 
On the other hand, degradable polymers (natural or synthetic)-based films 
have been utilized for drug delivery. They erode or dissolve in the placement site 
so that removal after placement is not required. Periodontal application of these 
films resulted in a significant improvement in clinical parameters. Among natural 
biopolymers, atelocollagen, a pepsin-solubilized type I collagen, has been 
investigated as a potential carrier for anti-bacterial agents in periodontal disease. 
Glutaraldehyde cross-linked atelocollagen prolonged tetracycline concentration in 
GCF for at least ten days(83). Gelatin, another natural polymer obtained from fish, 
was cross-linked and utilized for the delivery of chlorhexidine diacetate or 
chlorhexidine hydrochloride. In vitro data showed a varied sustained drug release 
kinetic from 4 to 80 hours, depending on the drug concentration and cross-linking 
degree of the polymer(86). Moreover, a chip that weighs approximately 6.9 mg and 
contains 2.5 mg of chlorhexidine gluconate in a biodegradable matrix of hydrolyzed 
gelatin cross-linked with glutaraldehyde has been developed and commercially 
available under the trade name Periochip®. It showed an initial burst release in the 
first 24 hours, followed by a constant slower release over about seven days. Due 
to its adhesive nature, it remains inside the pocket with no additional aids for 
retention which is an advantage compared to other biodegradable films. Chitosan 
film has also been utilized with taurine (antioxidant agent). Taurine augments the 
15 
 
wound healing ability of chitosan showing great potential to be used in 
inflammatory diseases such as periodontitis(87).  
 
Synthetic biodegradable polymers have also been used for sustained 
release of drug in the periodontal pocket. In one study, amoxicillin and 
metronidazole were combined into PLGA and showed a synergistic effect against 
E. limosum, which had been reported to be resistant to metronidazole(88). The 
films showed a sustained in vitro release over 16 days and drug concentrations in 
vivo were maintained above the MIC value. By contrast, PLGA films loaded with 
tetracycline hydrochloride showed very short residence time in the periodontal 
pockets with incomplete release of tetracycline(89). This might be explained due 
to the hydrophobic nature of PLGA matrix and the difference in physicochemical 
properties of the drugs. In another study, the water-soluble polymer Eudragit S1 
and non-water-soluble polymer Eudragit L1 were used to prepare films for the 
delivery of clindamycin(90). Another group also showed that minocycline 
embedded in PCL achieved sustained release of the drug within the periodontal 
pocket for seven days and concluded that this film would be a useful tool for 
periodontal disease treatment(84). Lastly, a clinico-laboratory study was 
performed for the treatment of periodontal disease using chlorhexidine-loaded 
Diplen-Denta films(91). This treatment was shown to be highly effective in 
individuals diagnosed with catarrhal gingivitis or generalized periodontitis. Overall, 
periodontal inserts, particularly biodegradable that do not need to be removed after 
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intra-pocket insertion, would be superior to non-biodegradable films and fiber 
delivery systems.   
 
        1.5.3 Injectable gels 
Gels are semisolid formulations used in numerous biomedical 
pharmaceutical applications. They are crosslinked polymer-based systems in 
which therapeutic agents can be physically or chemically incorporated to provide 
a sustained-release kinetic. Several hydrogels and oleogels receive intensive 
attention for the localized delivery of therapeutics into periodontal pockets since 
they are easy to prepare and administer and also their bio-adhesive property 
enhances the retention time in the periodontal pocket. 
Chitosan, a novel biodegradable natural polymer, in a gel form (1%, w/w) 
with or without 15% metronidazole, was effective in the treatment of chronic 
periodontitis(92). Elyzol® 25% is a dental gel contained metronidazole benzoate 
(40%) in a mixture of glyceryl monooleate (GMO) and triglyceride (sesame oil) 
developed for periodontitis treatment. A study compared the clinical and 
microbiological parameters after repeated local applications of 1% metronidazole 
or 1% chlorhexidine gels in periodontal pockets treated by scaling and root planing 
and obtained similar positive findings with both gels at 1% concentration(93). Chlo-
Site, a xanthan-based gel with 1.5% chlorhexidine, was evaluated following scaling 
and root planing in 30 patients of both genders having chronic periodontitis. Its 
clinical effects after topical subgingival application as an adjunct to scaling and root 
planing appeared to cause significant improvement compared with scaling and root 
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planing alone in individuals with chronic periodontitis(94). Furthermore, local 
delivery of 1% alendronate gel into the periodontal pocket has been utilized to 
prevent bone destruction associated with periodontitis. When locally delivered into 
periodontal pockets of patients with type 2 diabetes mellitus and chronic 
periodontitis as an adjunct to scaling and root planning, it resulted in a significant 
increase in the probing depth reduction, clinical attachment level gain, and 
improved bone fill compared to control (free gel)(42,95). Also, local simvastatin gel 
was applied locally in a 60-patient study as an adjunct to scaling and root planing 
and showed a greater decrease in the gingival index and probing depth and a 
clinical attachment level gain with a significant decrease in mean intrabony defect 
when compared to control group (SRP plus placebo)(53,96). Another study 
evaluated the effect of locally delivered atorvastatin (2% w/v) containing chitosan 
gel in the treatment of periodontitis in rats. Significant alveolar bone healing with 
anti-inflammatory effect was observed(97). 
Thermosensitive hydrogel systems have been utilized extensively in drug 
delivery, controlled release, and cell encapsulation applications. Their unique 
thermal reversible gelation property makes them an attractive delivery vehicle for 
regenerative applications in dentistry. They exist in solution form at room 
temperature and then rapidly convert to hydrogel at physiological temperature 
holding encapsulated drugs in their crosslinked structures. They can be an ideal 
intra-pocket delivery system as they can easily pass through into periodontal 
pocket where they solidify in situ and then deliver the therapeutic agent for a 
prolonged period. Atridox® is an injectable thermosensitive biodegradable gel 
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composed of 10% doxycycline hyclate dissolved in Atrigel® delivery system, which 
is a bioabsorbable, polymeric formulation composed of 36.7% poly (D-lactide) 
(PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Doxycycline 
concentrations in GCF reached nearly 1500 μg/mL two hours following treatment 
with Atridox® and maintained at 140 μg/mL at day 7. In another study, Atrigel® 
containing 5% sanguinarine was superior to the control in the treatment of adult 
periodontitis and the findings have been confirmed in a clinical trial(98). A study 
demonstrated a significant reduction in the clinical and microbiological parameters 
after using Elyzol® and Atridox®(99). Another thermosensitive hydrogel system 
composed of Poloxamer 407 and Carbopol 934P and containing propolis extract 
has been designed for periodontal disease treatment(100). The release of the 
propolis was controlled by the relaxation of polymer chains, and the greatest 
mucoadhesive property was achieved when using a 60:1 ratio of Poloxamer 407: 
Carbopol 934P. Recently, several poloxamer 407-based thermosensitive gel 
systems have been formulated, characterized, and evaluated in vitro for their 
potential application in periodontal disease treatment. An in situ gel using 
poloxamer 407 (20% w/v) and chitosan (0.5%, 1%, 1.5%, 2.0% 2.5% w/v) 
containing two antibiotics: levofloxacin and metronidazole was formulated with 
syringeable, thermo-responsive, and mucoadhesive properties(101). Other 
researchers developed a poloxamer 407-based hydrogel with the addition of 
Carbopol 934P to make it a pH-sensitive and mucoadhesive for the buccal delivery 
of curcumin to study its anti-inflammatory properties. The prepared hydrogel was 
easily syringeable and effective in terms of the reduction of the probing depth, 
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bleeding index and amount of plaque(102). The same hydrogel was also used to 
develop a dual-controlled release periodontal system containing ciprofloxacin and 
the anti-inflammatory enzyme serratiopeptidase(103). In another study, a 
thermosensitive mucoadhesive gel composed of poloxamer 407 (21% w/v), 
poloxamer 188 (2% w/v), and hydroxypropyl methylcellulose (HPMC) (0.5% w/v) 
was developed and characterized for the buccal delivery of the moxifloxacin. The 
formulation exhibited sustained drug release and showed a promising antibacterial 
efficacy against Aggregatibacter actinomycetemcomitans and Streptococcus 
mutans which are involved in periodontal infections(104). Moreover, an injectable 
antimicrobial delivery system for periodontal treatment based on 
chitosan/gelatin/β-glycerolphosphate hydrogel has been developed and showed 
no cytotoxic effects(105). Another recent study prepared and characterized a 
minocycline-loaded hydrogel composed of PLGA and N-methylpyrrolidone (NMP) 
as a promising treatment for periodontitis(106). Together, semi-solid formulations 
have been extensively investigated as a local delivery system for therapeutic 
agents in periodontal disease. Particularly, thermosensitive gels are attractive 
since their administration can be easily and rapidly performed with even 
distribution in the pocket. However, their mechanical strength and retention time 
are major concerns.  
 
      1.5.4 Microparticulate system  
This system consists of polymeric micro-sized particles into which drug 
molecules incorporated either physically or chemically for controlled release at the 
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target site. It is a highly stable system for the delivery of an optimum concentration 
of the drug in the periodontal pocket. Non-biodegradable as well as biodegradable 
polymers have been investigated for the preparation of microparticles. These 
materials include natural polymers, modified natural materials, and synthetic 
polymers. Among biodegradable polymers, PLGA is the most common one utilized 
for microparticles development. The drug release from PLGA-based microparticles 
depends upon the polymer (lactide: glycolide) ratio, molecular weight, crystallinity 
and pH of the medium.  Arestin®, 1 mg minocycline PLGA microspheres, is an 
approved microparticles delivery system for periodontal disease as an adjunct to 
mechanical therapy. When administered to treat chronic periodontitis, it was 
concluded that Arestin® combined with SRP is more effective and safer than SRP 
alone in reducing the signs of chronic periodontitis(107). However, a recent 
randomized clinical trial study concluded that the use of minocycline microspheres 
did not result in an additional benefit over SRP alone(108).   PLGA-based 
microparticles containing tetracycline has been also designed for periodontal 
disease therapy(109). These particles have been also suspended in Pluronic F127 
to form a thermosensitive hydrogel at body temperature and hold the 
microcapsules in the periodontal pocket for the duration of treatment. Furthermore, 
PLGA microparticles loaded with chlorhexidine free base, chlorhexidine 
digluconate were prepared with single emulsion, solvent evaporation 
technique(110). Recently, doxycycline microspheres were prepared by w/o/w 
double emulsion technique. The formulation achieved controlled delivery of 
doxycycline for up to 11 days and was also effective with respect to microbiological 
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and clinical parameters for up to three months(111). However, the retention of such 
formulations in the periodontal pocket needs more investigation and clarification. 
 
     1.5.5 Nanoparticulate system 
Recently, intensive research has been done worldwide utilizing 
nanotechnology to improve the effectiveness of drugs and minimizing their side 
effects. Nanoparticles provide several advantages compared to microparticles 
including high dispersibility in an aqueous medium, slow release rate, and high 
stability. Due to their nanosize, they can distribute deeply into regions that may be 
inaccessible to other delivery systems, such as the deep periodontal pockets. 
Hence, the frequency of administration would be reduced and a uniform 
distribution of the drug molecules over an extended period of time would be 
obtained(61). Formulating drugs into nanoparticles led to a dramatic change in 
their pharmacokinetic parameters and a subsequent reduction in drug dose(112). 
Nanoparticles (liposomes, micelles, or polymeric) have been used for periodontal 
drug delivery resulting in powder materials with a particle size in the range of 50–
180 nm. Several liposomal formulations of different therapeutic agents have been 
developed, characterized, and evaluated in vitro and in vivo for local treatment of 
periodontal disease and showed promising outcomes(113–115). However, 
liposomes have some limitations including physical and chemical stability, drug 
leakage, and difficulties in scaling up which might limit their use. Furthermore, 
recent PEG-based simvastatin micelles were developed for periodontitis(116). The 
study concluded that three weekly injections of these nanoparticles decreased 
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alveolar bone loss and inflammation in rats. Minocycline-loaded poly(ethylene 
glycol)-poly(lactic acid) nanoparticles were also prepared and evaluated in 
beagles(117). Effective minocycline concentrations were maintained in GCF for 12 
days [48]. In another study, triclosan-loaded polymeric (PLGA, poly-lactic-acid and 
cellulose acetate phthalate) nanoparticles were prepared by emulsification–
diffusion process and were tested in vivo in a periodontitis dog model, as a 
preliminary study. It was found that triclosan-loaded nanoparticles penetrated 
through the junctional epithelium(118). Moreover, Harungana madagascariensis 
leaf extract (HLE)-loaded PLGA nanoparticles were prepared using interfacial 
polymer deposition following the solvent diffusion method and its bactericidal 
activity was investigated in vitro. Formulating HLE into a nanoparticle system 
improved its antibacterial performance and reduced the bactericidal 
concentration(119). In another study, a multi-component release system 
composed of biodegradable nanoparticles which have bioadhesive properties 
encapsulated within a moisture sensitive microparticle was patented. The 
positively charged surfactant entrapped on the particle surface mediates the bio-
adhesive properties of the nanoparticles. This system can be formulated into any 
oral hygiene product including gels, chewing gums, toothpaste and mouthwash for 
the treatment and prevention of periodontal disease(120). In addition, antisense 
oligonucleotide- loaded chitosan-tripolyphosphate (TPP) nanoparticles were 
prepared by adding TPP after the formation of chitosan/oligonucleotide complex. 
The nanoparticles sustainably released oligonucleotides and have the potential to 
be used in periodontal diseases(121). Furthermore, nanoparticles can be 
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employed to counter the emergence and increase of bacterial resistance to 
multiple antibiotics. Antimicrobial enzymes can be conjugated to nanoparticles to 
produce an antibiotic-free treatment for microbial infections(122).  
 
     1.5.6 Miscellaneous 
Other local drug delivery systems have been developed for periodontium 
regeneration. In a study where the effects of local delivery of a simvastatin– 
alendronate–β-cyclodextrin (SIM–ALN–CD) conjugate for preventing experimental 
periodontitis bone loss was investigated, it was concluded that such a conjugate 




Periodontal disease is a major public health concern and the development 
of effective therapies to prevent the disease or treat/regenerate periodontal tissues 
is an ultimate goal. Its management has traditionally focused on the use of 
mechanical procedures plus systemic antimicrobial agents to reduce pathogen 
load and to prevent disease progression. However, the constant unraveling of 
pathogenesis behind periodontal diseases has shifted the route of drug 
administration in periodontal therapy, from systemic to intra-pocket-targeted 
delivery systems. These local systems have been successful and shown positive 
outcomes in a large number of clinical studies in terms of overall periodontal 
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health. However, concerted efforts in developing ideal intra-pocket drug delivery 
systems are still needed. Most of the currently available formulations, which 
focused only on delivering anti-microbial agents, suffer from several limitations 
including lack of osteotropicity or tooth binding, the removal of non-biodegradable 
delivery systems, lack of penetration into deeper regions of periodontal pocket and 
poor patient compliance, indicative of a low clinical translation potential. Therefore, 
and as will be discussed in the next two chapters, the work of this thesis focused 
on developing novel intra-pocket delivery systems of bone anabolic and host 
modulation agents for the treatment of periodontal diseases, in consideration of 
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As discussed in Chapter 1, periodontitis is an oral inflammatory disease that 
affects the integrity of tooth-supporting tissues including gingiva, periodontal 
ligament, cementum, and alveolar bone.  The pathogenic bacterial population and 
host immune response are considered as keystones in the emergence and 
persistence of the disease(1).  Non-surgical treatment options are limited to plaque 
(biofilm) removal which aim to reduce inflammation(2) followed by administration 
of local and systemic antibiotics to minimize bacterial load in the periodontal 
pocket(3,4).  Additionally, nonsteroidal anti-inflammatory medications, sub-
antimicrobial doses of doxycycline, and growth factors have all been utilized as 
host modulation agents to reduce disease progression(5,6).  However, their effect 
on the inflammation-induced alveolar bone loss is limited.  Hence, there is an 
urgent need for the development of a therapeutic strategy that can 
prevent/regenerate alveolar bone loss.  
As discussed in Chapter 1, statins are a class of anti-hyperlipidemic agents 
which have been found to ameliorate inflammation and to induce the expression 
of bone morphogenic protein-2 (BMP-2) leading to substantial osteogenic 
effects(7,8).  They have been considered as potential therapeutic candidates for 
periodontal disease.  However, their aqueous solubility and osteotropicity are 
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major limitations. Local delivery systems of SIM have been developed to enhance 
solubility and provide a sustained release, and have shown potential protection of 
the periodontal tissues (9,10).  
In this chapter, a novel strategy to address the limitations associated with 
the clinical utility of SIM for periodontal disease is discussed. A SIM prodrug was 
developed by conjugating a SIM trimer to osteotropic pyrophosphate (PPi).   The 
prodrug (SIM-PPi) was fully characterized, and its therapeutic efficacy was 















2.2 METHODS AND MATERIALS 
 
  2.2.1 Materials 
 
Simvastatin was purchased from Zhejiang Ruibang Laboratories (Wenzhou, 
Zhejiang, China) Hydroxyapatite microparticles (HA, DNA grade Bio-Gel HTP gel) 
were purchased from Bio-Rad (Hercules, CA, USA).  Mouse macrophage RAW 
264.7 cells, osteoblast MC3T3-L1 cells, and Dulbecco’s Modified Eagle Medium 
(DMEM) were originally purchased from ATCC (Manassas, VA, USA). Minimum 
Essential Media (alpha-MEM) and trypsin-EDTA were purchased 
from Gibco (Grand Island, NY, USA).  Fetal bovine serum (FBS) was obtained 
from Gemini BenchMark (West Sacramento, CA).  Silver nitrate was purchased 
from RICCA Chemical Company (Arlington, TX).  Sodium thiosulfate was 
purchased from Alfa Aesar (Haverhill, MA).  All other reagents and solvents, if not 
specified, were obtained from either Fisher Scientific (Pittsburgh, PA, USA) or 
Acros Organics (Morris Plains, NJ, USA). 
      2.2.2 Synthesis of the simvastatin-pyrophosphate prodrug (SIM-PPI) 
Synthesis of compound 1 
Simvastatin (6.27g, 15 mmol), butane-1,4-diol (27.3g, 300 mmol) and p-
toluenesulfonic acid monohydrate (TsOHH2O, 285 mg, 1.5mmol) were dissolved 
in anhydrous CH2Cl2 (30 mL).  The solution was stirred at room temperature for 3 
hr.  NaHCO3 (saturated solution, 15 mL) and ethyl acetate (100 mL) were added 
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and then washed with brine (80 mL3).  The organic phase was dried over Na2SO4 
and then the solvent was removed.  The residue was purified by flash column 
chromatography (ethyl acetate/hexanes = 3/1) to give compound 1 (5.76 g), yield: 
75.6%. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5.97 (d, J = 9.7 Hz, 1H), 5.78 (dd, J = 9.7 
Hz, 6.3 Hz，1H), 5.49 (s, 1H), 5.38 (d, J = 2.5 Hz, 1H), 4.26 (d, J = 3.8 Hz, 1H), 
4.20 (s, 1H), 4.16 (t, J = 6.5 Hz, 2H), 3.83 (s, 1H), 3.78 (br, 1H), 3.67 (t, J = 6.0 Hz, 
2H), 2.49 (s, 1H), 2.48 (s, 1H), 2.43 (m, 1H), 2.39 (s, 1H), 2.36 (dd, J = 12.3 Hz, 
6.2Hz, 1H), 2.24 (d, J = 10.6 Hz, 1H), 1.95 (m, 2H),  1.76 (m, 2H), 1.60-1.70 (m, 
4H), 1.45-1.60 (m, 5H), 1.26 (m, 1H), 1.19 (m, 1H), 1.12 (s, 3H), 1.11 (s, 3H), 1.08 
(d,  J = 7.4 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H), 0.83 (t, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 178.14, 172.27, 133.04, 131.54, 129.45, 
128.20, 72.15, 68.95, 68.08, 64.50, 61.96, 42.90, 42.29, 41.94, 37.61, 36.19, 
34.74, 32.93, 32.89, 30.42, 28.94, 27.19, 24.98, 24.70, 24.59, 24.14, 23.00, 13.79, 
9.21. 
MS (ESI): m/z = 531.1 (M + Na+), calculated MW = 508.3. 
Synthesis of compound 2 
Compound 1 (6.5 g, 12.8 mmol) and imidazole (1.74 g, 25.6 mmol) were dissolved 
in anhydrous CH2Cl2 (30 mL) and cooled to 0 °C.  t-Butyldimethylsilyl chloride 
(TBSCl, 2.10 g, 14 mmol) was added.  The solution was stirred at 0 °C for 3 hr.  
Ethyl acetate (100 mL) were added and then washed with brine (80 mL3).  The 
organic phase was dried over Na2SO4 and then the solvent was removed.  The 
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residue was purified by flash column chromatography (ethyl acetate/hexanes = 
1/1) to give compound 1 (7.18 g), yield: 90.2%. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5.93 (d, J = 9.7 Hz, 1H), 5.73 (dd, J = 9.7 
Hz, 6.3Hz，1H), 5.44 (s, 1H), 5.34 (d, J = 2.6 Hz, 1H), 4.21, (br, 1H), 4.09 (t, J = 
6.6 Hz, 2H), 4.07 (s, 1H), 3.79, (s, 1H), 3.73 (br, 1H), 3.59 (t, J = 6.2 Hz, 2H), 2.44 
(s, 1H), 2.43 (s, 1H), 2.39 (m, 1H), 2.33 (dd, J = 11.4 Hz, 6.1Hz), 2.19 (d, J = 10.6 
Hz, 1H), 1.90 (br, 2H),  1.65 (m, 2H), 1.53 (m, 9H), 1.21 (m, 1H), 1.14 (m, 1H), 
1.08 (s, 3H), 1.07 (s, 3H), 1.04 (d,  J = 7.4 Hz, 3H), 0.85 (s, 9H), 0.82 (s, d, J = 7.0 
Hz, 3H), 0.78 (t, J = 7.5 Hz, 3H), 0.01 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.81, 172.18, 132.93, 131.50, 129.28, 
128.14, 72.02, 68.81, 67.92, 64.47, 62.32, 42.76, 42.27, 41.71, 37.52, 36.13, 
34.69, 32.82, 30.34, 28.96, 27.12, 25.76, 25.01, 24.62, 24.51, 24.10, 22.92, 18.10, 
13.71, 9.13, -5.50 
MS (ESI): m/z = 645.5 (M + Na+), calculated MW = 622.4. 
Synthesis of compound 3 
Compound 2 (5.35 g, 7 mmol), triethylamine (2.12 g, 3 mmol) and 4-
dimethylaminopyridine (DMAP, 170 mg, 1.4 mmol) were dissolved in anhydrous 
CH2Cl2 (20 mL) and cooled to 0 °C.  Ac2O (1.78 g, 17.5 mmol) was added.  The 
solution was stirred at 0 °C for 0.5 hr.  Ethyl acetate (70 mL) was added and 
washed with HCl (25 mL, 1 M) and brine (100 mL).  The organic phase was dried 
over Na2SO4 and then the solvent was removed to give crude product compound 
3 (4.90 g).  It was used directly in the next reaction without further purification. 
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1H NMR (500 MHz, CDCl3): δ (ppm) = 5.93 (d, J = 9.7 Hz, 1H), 5.73 (dd, J = 9.7 
Hz, 6.3Hz，1H), 5.45 (s, 1H), 5.30 (d, J = 2.6Hz, 1H), 5,19 (pent, J = 6.2 Hz), 4.84 
(m, 1H),  4.06 (t, J = 6.6 Hz, 2H), 3.60 (t, J = 6.2 Hz, 2H), 2.57 (s, 1H), 2.56 (s, 1H), 
2.39 (m, 1H), 2.33 (dd, J = 11.4Hz, 6.1Hz), 2.19 (d, J = 11.7 Hz, 1H), 2.02 (s, 3H), 
1.96 (s, 3H), 1.93 (m, 3H), 1.82 (m, 1H),  1.60-1.70 (m, 4H), 1.40-1.60 (m, 5H), 
1.31 (m, 1H), 1.14  (m, 1H), 1.08 (s, 3H), 1.07 (s, 3H), 1.04 (d,  J = 7.4 Hz, 3H), 
0.85 (s, 9H), 0.82 (d, J = 7.0 Hz, 3H), 0.78 (t, J = 7.5 Hz, 3H), 0.01 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.32, 170.33, 169.87, 169.81, 132.68, 
131.41, 129.53, 128.26, 70.95, 67.73, 67.63, 64.51, 62.34, 42.74, 38.58, 37.57, 
37.39, 36.25, 32.81, 32.72, 30.99, 30.35, 28.96, 27.14, 25.78, 25.05, 24.59, 24.53, 
23.24, 22.89, 21.03, 20.88, 18.14, 13.64, 9.14, -5.48 
MS (ESI): m/z = 729.7 (M + Na+), calculated MW = 706.5. 
Synthesis of compound 4 
Compound 3 (4.90g, 6.9 mmol) was dissolved in a mixture solution (MeOH/CH2Cl2 
= 1/1, 20 mL) and cooled to 0 °C.  TsOH monohydrate (133 mg, 0.7 mmol) was 
added.  The solution was stirred at 0 °C for 1 hr.  Ethyl acetate (100 mL) was added 
and then washed with brine (80 mL3). The organic phase was dried over Na2SO4 
and then the solvent was removed.  The residue was purified by flash column 
chromatography (ethyl acetate/hexanes = 1/1) to give compound 4 (3.69 g), yield: 
89.0% for two steps. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5.88 (d, J = 9.7 Hz, 1H), 5.66 (dd, J = 9.7 
Hz, 6.3Hz，1H), 5.40 (s, 1H), 5.23 (d, J = 2.6Hz, 1H), 5.13 (pent, J = 6.2 Hz), 4.77 
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(m, 1H),  4.06 (m, 2H), 3.60 (t, J = 6.2 Hz, 2H), 2.514 (s, 1H), 2.510 (s, 1H), 2.50 
(t, J = 3.8 Hz, 1H), 2.33 (m, 1H), 2.26 (dd, J = 11.4Hz, 6.1Hz, 1H), 2.19 (d, J = 
11.7Hz, 1H), 1.96 (s, 3H), 1.93 (s, 3H), 1.86 (m, 3H), 1.76 (m, 1H),  1.45-1.65 (m, 
9H), 1.26 (m, 1H), 1.06 (m, 1H), 1.02 (s, 3H), 1.01 (s, 3H), 0.98 (d,  J = 7.4 Hz, 
3H), 0.77 (d, J = 7.0 Hz, 3H), 0.73 (t, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.34, 170.38, 169.86, 169.78, 132.54, 
131.25, 129.40, 128.13, 70.90, 67.64, 67.59, 64.34, 61.67, 42.63, 38.53, 37.48, 
37.23, 36.12, 32.67, 32.56, 30.91, 30.22, 28.74, 27.00, 24.80, 24.46, 24.39, 23.14, 
22.76, 20.90, 20.75, 13.50, 9.02 
MS (ESI): m/z = 615.4 (M + Na+), calculated MW = 592.4. 
Synthesis of compound 5 
Compound 2 (2.50 g, 4.0 mmol), succinic anhydride (1.6 g, 16 mmol), triethyl 
amine (2.0 g, 20 mmol) and DMAP (146 mg, 1.2 mmol) were dissolved in 
anhydrous CH2Cl2 (20 mL).  The solution was stirred overnight.  Ethyl acetate (70 
mL) was added and then washed with HCl (25 mL, 1 M) and brine (100 mL).  The 
organic phase was dried over Na2SO4 and then the solvent was removed.  The 
residue was purified by flash column chromatography (ethyl acetate/hexanes = 1/1 
and trace amount of acetic acid) to give compound 5 (2.89 g), yield: 87.8%. 
1H NMR (500 MHz, CDCl3): δ (ppm) =  10.79 (br, 2H), 5,96 (d, J = 9.7 Hz, 1H), 
5.75 (dd, J = 9.7 Hz, 6.3Hz，1H), 5.48 (s, 1H), 5.35 (d, J = 2.6 Hz, 1H), 5,23 (pent, 
J = 6.2 Hz), 4.89 (m, 1H),  4.08 (t, J = 6.6 Hz, 2H), 3.63 (t, J = 6.2 Hz, 2H), 2.55-
2.75 (m , 10H), 2.42 (s, 1H), 2.34 (dd, J = 11.4 Hz, 6.1Hz, 1H), 1.94 (m, 1H), 1.87 
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(s, 3H),  1.84 (m, 1H), 1.60-1.70 (m, 4H), 1.40-1.60 (m, 5H), 1.34 (m, 1H), 1.105 
(s, 3H), 1.098 (s, 3H), 1.06 (d,  J = 7.4 Hz, 3H), 0.85 (s, 9H), 0.81 (d, J = 7.0 Hz, 
3H), 0.80 (t, J = 7.5 Hz, 3H), 0.05 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 178.11, 177.32, 176.71, 171.66, 171.17, 
170.07, 132.79, 131.43, 129.57, 128.26, 71.55, 68.12, 68.04, 64.62, 62.57, 42.92, 
38.43, 37.73, 37.47, 36.13, 32.86, 31.10, 30.35, 29.02, 28.93, 28.79, 27.16, 25.85, 
25.03, 24.60, 24.58, 23.60, 22.97, 18.23, 13.69, 9.19, -5.42. 
MS (ESI): m/z = 845.0 (M + Na+), calculated MW = 822.4. 
Synthesis of compound 6 
Compound 5 (1.65 g, 2.0 mmol) and DMAP (73 mg, 0.6 mmol) were dissolved in 
anhydrous CH2Cl2 (20 mL) and cooled to 0 °C.  N,N'-Dicyclohexylcarbodiimide 
(DCC, 1.24 g, 6.0 mmol) in anhydrous CH2Cl2 (5 mL) was added and then 
compound 4 (2.48 g, 4.6 mmol) was added.  The solution was stirred at 0 °C for 1 
hr. Dichloromethane (70 mL) was added and filtered to remove the solid. The 
filtrate was then concentrated. The residue was purified by column 
chromatography (ethyl acetate/hexanes = 1/2 to 1/1) to give compound 6 (3.53 g), 
yield: 89.6%. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5,93 (d, J = 9.7 Hz, 3H), 5.73 (dd, J = 9.7 
Hz, 6.3Hz，3H), 5.45 (s, 3H), 5.29 (d, J = 2.6 Hz, 3H), 5,18 (pent, J = 6.1 Hz, 3H), 
4.83 (m, 3H),  4.08 (m, 10H), 3.58 (t, J = 6.2 Hz, 2H), 2.59 (s, 3H), 2. 56 (m, 14H), 
2.34 (dd, J = 11.4 Hz, 6.1Hz, 1H), 2.21 (d, J = 11.7 Hz, 1H), 2.02 (s, 6H), 1.98 (s, 
6H), 1.94 (m, 9H), 1.87 (m, 3H), 1.40-1.70 (m, 27H), 1.31 (m, 3H), 1.14 (m, 3H), 
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1.07 (s, 9H), 1.06 (s, 9H), 1.03 (d,  J = 7.4 Hz, 9H), 0.84 (s, 9H), 0.82 (d, J = 7.0 
Hz, 9H), 0.78 (t, J = 7.5 Hz, 9H), 0.01 (s, 6H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.28, 177.23, 171.98, 171.85, 171.59, 
171.12, , 170.29, 169.78, 169.76, 169.74, 132.68, 132.62, 131.39, 131.36, 129.49, 
129.46, 128.21, 71.34, 70.89, 67.91, 67.64, 67.58, 64.46, 63.94, 63.93, 63.87, 
63.85, 62.31, 60.12, 42.69, 38.51, 38.29, 37.57, 37.33, 36.20, 32.76, 32.67, 30.96,  
30.30, 28.99, 28.92, 28.76, 28.72, 27.09, 25.75, 25.01, 24.55, 24.51, 24.48, 23.40, 
23.21, 22.84, 20.99, 20.83, 18.10, 14.02, 13.63, 13.60, 9.11, 05.51 
MS (ESI): m/z = 1994.9 (M + Na+), calculated MW = 1971.4. 
Synthesis of compound 7 
Compound 6 (3.13 g, 1.59 mmol) was dissolved in a mixture solution 
(methanol/CH2Cl2 = 1/1, 20 mL) and cooled to 0 °C.  TsOH monohydrate (60.4 mg, 
0.32 mmol) was added.  The solution was stirred at 0 °C for 1 hr.  Ethyl acetate 
(100 mL) was added and then washed with brine (80 mL3). The organic phase 
was dried over Na2SO4 and then the solvent was removed.  The residue was 
purified by flash column chromatography (ethyl acetate/hexanes = 1/1) to give 
compound 7 (2.59 g), yield: 87.8%. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5.97 (d, J = 9.7Hz, 3H), 5.77 (dd, J = 9.7 
Hz, 6.3Hz，3H), 5.50 (s, 3H), 5.33(d, J = 2.6Hz, 3H), 5.23 (pent, J = 6.1 Hz, 3H), 
4.87 (m, 3H), 4.11 (m, 10H), 3.66 (t, J = 6.2 Hz, 2H), 2.61 (m, 14H), 2.43 (s, 3H), 
2.34 (dd, J = 11.4 Hz, 6.1Hz, 3H), 2.21 (d, J = 11.7 Hz, 3H), 2.06 (s, 6H), 2.04 (s, 
6H), 1.94 (m, 9H), 1.85 (m, 3H), 1.50-1.70 (m, 24H), 1.46 (m, 3H), 1.33 (m, 3H), 
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1.13 (m, 3H), 1.11 (s, 9H), 1.10 (s, 9H), 1.07 (d,  J = 7.4 Hz, 9H), 0.86 (s, 9H), 0.82 
(d, J = 7.0 Hz, 9H), 0.82 (t, ,  J = 7.4 Hz, 9H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.45, 172.15, 172.09, 171.78, 171.26, 
170.47, 169.94, 169.84, 177.45, 172.15, 172.09, 171.78, 171.26, 170.47, 169.94, 
169.84, 132.74, 131.45, 129.63, 128.30, 71.43, 71.00, 68.08, 67.75, 67.71, 64.50, 
64.06, 64.00, 62.07, 42.81, 38.61, 38.47, 37.66, 37.43, 36.29, 32.87, 32.86, 32.76, 
31.16, 31.06, 30.40, 29.09, 29.03, 28.86, 28.80, 27.19, 25.09, 24.98, 24.66, 24.64, 
24.61, 24.58, 23.54, 23.31, 22.94, 21.10, 20.95, 13.73, 13.69, 9.21, 9.20 
MS (ESI): m/z = 1880.6 (M + Na+), calculated MW = 1857.4 
Synthesis of compound 8 
Compound 7 (386 mg, 0.21 mmol) and DMAP (5.1 mg, 0.04 mmol) were dissolved 
in anhydrous dichloromethane (20 mL) and cooled to 0 °C.  DCC (65g, 0.315mmol) 
in anhydrous dichloromethane (3 mL) was added and then bromoacetic acid (38.4 
mg, 0.27 mmol) was added. The solution was stirred at 0 °C for 1 hr.  
Dichloromethane (70 mL) was added and filtered to remove the solid.  The filtrate 
was then concentrated.  The residue was purified by column chromatography 
(ethyl acetate/hexanes = 1/2) to give compound 8 (336 mg, 0.172 mmol), yield: 
82.1%. 
1H NMR (500 MHz, CDCl3): δ (ppm) = 5.97 (d, J = 9.7Hz, 3H), 5.77 (dd, J = 9.7Hz, 
6.3Hz，3H), 5.50 (s, 3H), 5.33(d, J = 2.6 Hz, 3H), 5.23 (pent, J = 6.1 Hz, 3H), 4.87 
(m, 3H), 4.20 (t, 5.8 Hz, 2H), 4.11 (m, 10H), 3.85 (s, 2H), 3.65 (t, J = 6.2 Hz, 2H), 
2.63 (s, 6H),  2.63 (s, 6H), 2.61 (s, 4H), 2.59 (s, 4H), 2.43 (s, 3H), 2.34 (dd, J = 
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11.4 Hz, 6.1 Hz, 3H), 2.22 (d, J = 11.7Hz, 3H), 2.06 (s, 6H), 2.04 (s, 6H), 1.94 (m, 
9H), 1.85 (m, 3H), 1.50-1.70 (m, 24H), 1.46 (m, 3H), 1.33 (m, 3H), 1.13 (m, 3H), 
1.11 (s, 9H), 1.10 (s, 9H), 1.07 (d,  J = 7.4 Hz, 9H), 0.86 (d,  J = 7.0Hz, 9H), 0.82 
(t, ,  J = 7.4Hz, 9H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 177.39, 177.35, 172.06, 171.94, 171.71, 
171.20, 170.40, 169.87, 169.77, 167.07, 132.70, 131.42, 129.59, 128.27, 71.38, 
70.96, 67.95, 67.71, 67.67, 65.52, 64.02, 64.00, 63.98, 63.94, 63.89, 42.77, 38.58, 
38.35, 37.67, 37.62, 37.40, 36.26, 32.84, 32.82, 32.73, 31.07, 31.02, 30.37, 29.05, 
28.98, 28.82, 28.76, 27.15, 25.68, 25.06, 24.95, 24.63, 24.61, 24.58, 24.55, 23.50, 
23.28, 22.90, 21.07, 20.91, 13.70, 13.66, 9.16. 
Synthesis of compound 9 
Compound 8 (300 mg, 0.154 mmol) was dissolved in anhydrous acetonitrile (5 mL) 
and cooled to 0°C.  Tris(tetrabutylammonium) hydrogen pyrophosphate (277 mg, 
0.308 mmol) was added.  The solution was stirred at 0 °C for 1 hr.  The organic 
solvent was removed.  The residue was then dissolved in water and the solution 
went through the sodium resin to exchange the cation to sodium.  The elution was 
then lyophilized.  The residue was then purified by cellulose column 
chromatography (isopropanol/acetonitrile/H2O = 1:1:2) to give product compound 
9 (176 mg), yield: 54.1%. 
1H NMR (500 MHz, DMSO): δ (ppm) = 5.95 (d, J = 9.7 Hz, 3H), 5.77 (dd, J = 9.7 
Hz, 6.3Hz，3H), 5.50 (s, 3H), 5.2 (s, 3H), 5.11 (pent, J = 6.1 Hz, 3H), 4.76 (m, 3H), 
4.35 (d, 6.1 Hz, 2H), 4.09 (s, 2H), 4.03 (s, 8H), 2.63 (m, 6H),  2.56 (m, 12H), 2.47 
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(s, 3H), 2.38 (dd, J = 11.4 Hz, 6.1Hz, 3H), 2.24 (d, J = 11.7 Hz, 3H), 1.98 (s, 6H), 
1.97 (s, 6H), 1.94 (m, 9H), 1.85 (m, 3H), 1.50-1.70 (m, 24H), 1.46 (m, 3H), 1.33 
(m, 3H), 1.13 (m, 3H), 1.04 (s, 9H), 1.02 (s, 9H), 1.01 (d,  J = 7.4 Hz, 9H), 0.81 (d,  
J = 7.0 Hz, 9H), 0.76 (t, ,  J = 7.4Hz, 9H). 
31P NMR (202.5MHz, DMSO): δ (ppm) = -9.46, -10.67. 
 
         2.2.3 Comparing aqueous solubility of SIM-PPi and SIM 
 
This experiment was conducted to compare the aqueous solubility of SIM-PPi and 
free SIM.  The solubility values of SIM-PPi and SIM were obtained by measuring 
equilibrium solubility after adding the analyte to the testing medium for a 
predetermined period of time(11,12).  Briefly, SIM-PPi and SIM, (1 mg/mL) each, 
were added to either deionized water or phosphate buffer in microcentrifuge tubes.  
The suspensions were agitated on a rotor at 22 ± 2 C for 48 hr to reach the 
equilibrium.  The mixtures were then centrifuged (2,000 rpm, 5 min) to settle the 
undissolved drug.  The supernatants (saturated solutions) were obtained by 
filtering through 0.2 µm syringe filters, and then the SIM-PPi and SIM 
concentrations were measured using a UV spectrophotometer (SpectraMax M2, 





       2.2.4 In vitro hydroxyapatite (HA) binding assay 
 
To predict the binding of SIM-PPi to HA, which is the primary inorganic component 
of natural hard tissues, an in vitro binding test was performed using HA particles 
(Bio-Gel HTP, particle size is a range of 10-90 um, Bio-Rad).  Briefly, SIM-PPi (1 
mg/mL) was dissolved in 4 mL 25% isopropyl alcohol (1 mL of isopropyl alcohol 
diluted in 3 mL of 1.3 PBS to achieve final concentration of 1 PBS composed of 
11.9 mM phosphates, 137 mM sodium chloride, and 2.7 mM potassium chloride).  
HA (100 mg) was then added to the solution.  The PBS solution of alendronate 
(ALN) and SIM acid were separately prepared and mixed with HA (100 mg) for the 
binding analysis.  All binding media contained 11.9 mM phosphates, 137 mM 
sodium chloride, and 2.7 mM potassium chloride.  All three suspensions were 
agitated in micro-centrifuge tubes on a rotary mixer for varying lengths of time (30 
min, 2 hr and 6 hr).  At the end of each time point, the HA was spun down by 
centrifuging at 85 g for 5 min.  The binding affinity was assessed by measuring 
the relative concentration of SIM-PPi, SIM, and ALN in the supernatants.  The 
concentrations of SIM-PPi and SIM was detected by measuring the absorbance at 
230 nm using a UV spectrophotometer (SpectraMax M2, Molecular Devices, 
Sunnyvale, CA, USA).  The concentration of ALN was measured using the 









where X is the initial concentration (1 mg/mL) and Y is the concentration in the 
supernatant after incubation with HA. 
 
      2.2.5 Cell culture 
 
Cell viability assay  
Mouse macrophage RAW 264.7 and osteoblast MC3T3-L1 cell lines were cultured 
in Dulbecco’s modified Eagle Medium (DMEM) and Minimum Essential Media 
(MEM), respectively.  Each medium was supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (basal growth mediums).  Cells were 
incubated at 37 C in 5% CO2 to 90% confluence.  Cellular toxicity of SIM-PPI was 
evaluated using the 3-(4,5-dimethyl-thiazol-2yl)-2,5- diphenyltetrazoliumbromide 
(MTT) assay.  Briefly, RAW 264.7 and MC3T3-L1 cells were seeded in 96 well 
plates (1×104 cells/well) and treated with various concentrations of SIM-PPi, free 
SIM (0.01 nM to 1 mM, SIM equivalent), and free PPi (PPi in SIM-PPi equivalent), 
and then incubated for 24, 48 and 72 hr.  Following each time point, 10 µL of MTT 
reagent were added to each well and further incubated for 4 hr at 37 C.  MTT 
detergent reagent (100 µL) was added to each well to solubilize deposited 
formazan, then incubated in the dark at room temperature for 2 hr.  The 
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absorbance of each well was recorded at 570 nm using a microplate reader 
(SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). 
 
Measurement of LPS-induced cytokine  
LPS-induced pro-inflammatory cytokines were measured to investigate whether 
SIM-PPi retains the anti-inflammatory property of SIM.  RAW 264.7 cells were 
seeded into 24-well plate (2×105 cells/well) in 1 mL medium and incubated 
overnight.  The cells were pre-treated with 100 nM SIM or its equivalent SIM-PPi 
or PPi (PPi in SIM-PPi equivalent) for 1 hr before LPS challenge (1 µg/mL); the 
cells were then incubated in a 37 C, 5% CO2 incubator for 24 hr.  Supernatants 
were collected and centrifuged, then stored at -80 C until assayed for IL-6 and IL-
1β concentrations using ELISA kits according to the manufacturer’s protocols 
(Invitrogen).  
 
Measurement of alkaline phosphatase (ALP) activity 
Intracellular ALP was measured using p-nitrophenyl phosphate as a substrate to 
investigate whether SIM-PPi retains the osteoinductive property of SIM.  Briefly, 
MC3T3-L1 cells were seeded in 24-well plates at a density of 4×104 cells/well in 
the basal growth medium.  At 80% confluence, 100 nM SIM or its equivalent of 
SIM-PPi or PPi (PPi in SIM-PPi equivalent) were added to the basal growth 
medium supplemented with 4 mM inorganic phosphate as a phosphate ions 
source, and the incubation was continued with medium changed every 72 hr.  A 
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negative control group (con-) was cultured in only basal growth medium to observe 
any spontaneous differentiation.  Also, a positive control group (con+) was 
included and cultured in an osteogenic medium which was composed of basal 
growth medium, 4 mM inorganic phosphate, and osteoinductive supplements (0.28 
mM ascorbic acid and 100 nM dexamethasone).  After 3, 7, and 14 days, the 
culture medium was removed, and cell lysate was prepared according to the assay 
protocol.  The cells were washed twice with ice-cold phosphate buffered saline 
(PBS) followed by scraping the cells with 100 µl of ice-cold lysis buffer.  The cells 
were homogenized with the lysis buffer and centrifuged at high speed (13,000g 
for 3 min); the supernatants were frozen at -20 C until assayed for the ALP activity 
using a commercial ALP assay kit (BioVision Incorporated, Milpitas, CA).  
 
Alizarin red S staining and quantification  
To visualize calcium deposition by differentiated osteoblasts, MC3T3-L1 cells in a 
24-well plate were stained with Alizarin red S (ARS) after 28 days of culture with 
medium change every 72 hr.  Briefly, after washing the cellular monolayer with 
PBS, cells were fixed with 10% formalin for 30 min at room temperature, washed 
twice with DI water, and then stained with 2% ARS solution (pH 4.3) at room 
temperature in the dark for 45 min.  Cells were then washed five times with DI 
water and observed for the presence of calcium deposition as identified by red 
color presence.  ARS staining was quantified using the method described by 
Gregory CA., et al (14).  Briefly, following cells staining and washing, the plate was 
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placed in the freezer overnight to dry samples, and then 0.2 mL of 10% acetic acid 
in each well was added, and the plate was incubated at room temperature with 
shaking for 30 min.  Cells with acetic acid were then scrapped and collected in a 
micro-centrifuge tube, and vortexed for 30 seconds, followed by heating for 10 min 
at 85 C, and then cooling in an ice bath.  After centrifugation at 20,000 g for 15 
min, supernatants were collected, and adjusted pH to 4.3 with 10% ammonium 
hydroxide (75 µL).  Lastly, each sample (50 µL) was placed in an opaque-walled 
96-well plate with clear bottom and absorbance measured at 405 nm using a 
microplate reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA).   
    
von Kossa staining 
To further visualize and confirm the mineralized nodules, cells were stained with 
von Kossa stain after 28 days in culture with medium change every 72 hr; wherein 
silver ions replace calcium and react with phosphate under strong light to be seen 
as metallic silver.  Cells were washed and fixed in 10% formalin for 30 min, washed 
with DI water, and then incubated with 5% silver nitrate solution (RICCA Chemical 
company) at room temperature under bright light for 45 minutes or until mineral 
deposits turned black or dark brown.  After that, cells were washed 3 times with DI 
water, followed by incubating with 5% sodium thiosulfate (Alfa Aesar) for 5 min to 
remove unreacted silver.  After washing with ID water five times, wells were 




2.2.6 Evaluation of SIM-PPi’s therapeutic efficacy on an experimental 
periodontitis rat model  
Sprague Dawley rats (female, 10-month-old, retired breeders) were purchased 
from Envigo.  The animals were acclimated for one week prior to any experimental 
procedure.  Rats were divided randomly into four groups: experimental 
periodontitis with saline injection; experimental periodontitis with SIM treatment; 
experimental periodontitis with PPi treatment; experimental periodontitis with SIM-
PPi treatment (Table I).  A power analysis was performed to determine the number 
of animals needed to show a 30% difference in bone area stimulated by 
simvastatin prodrug compared to a control.  This analysis used data from previous 
studies(15,16).  In order to detect a greater than 30% change in bone 80% of the 
time when testing at the 5% level of significance (assuming normality of the data), 
at least 5 animals would be needed in each group.  Since 8 rats/group was used 
in a previous study testing the same ligature-induced periodontitis model(9), we 
used the same animal group size.  Silk ligatures were used to induce the 
experimental periodontitis as previously described(9).  Briefly, each rat was 
anesthetized using a chamber attached to isoflurane vaporizer (1- 4% isoflurane 
and 100% oxygen), followed by body weight measurement.  To maintain 
anesthesia during experimental procedures, a nose cone (0.5% - 2% isoflurane 
and 100% oxygen) was applied throughout the entire experimental procedure.  
Experimental periodontitis was induced in all groups by gently tightening a 4-0 silk 
ligature around the maxillary 2nd molars in both sides.  All animals were monitored 
and checked weekly to monitor the progression of periodontitis.  Post-procedure 
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analgesic (flunixin 2.5 mg/kg, s.c. every 12 hr) was given when signs of pain were 
observed.  After 2 weeks, ligatures were removed.  Different treatments including 
SIM-PPi (dissolved in 25% isopropyl alcohol as described in the HA binding study, 
2.56 mg, equivalent to 1.5mg SIM), SIM acid (dissolved in PBS, 1.56 mg, 
equivalent to 1.5 mg of SIM), and PPi (dissolved in PBS, 0.26 mg, equivalent to 
the PPi content in SIM-PPi) were locally injected (10µL) into the palatal gingiva 
between the maxillary first molar (M1) and second molar (M2) on the first day of 
week 1, 2 and 3 after ligature placement.  In the treatment of human periodontitis, 
this local delivery would be accompanied by scaling and root planing, but lack of 
long-term root contamination imprecise root planing with the rat model have led to 
its omission in most recent local drug-delivery studies(17–19).  At week 4, all 
animals were euthanized using CO2 asphyxiation followed by dissecting the entire 
palate including all three molars and placed in 10% formalin for µ-CT and 
histological evaluations.  All animal procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of University of Nebraska Medical 
Center (UNMC). 
 
2.2.7 Micro-computed tomography (µ-CT) analysis 
 
At the end-point, palates including all three molars on both sides were collected 
and fixed in 10% formalin.  All samples were scanned using a micro-CT imaging 
system (Bruker SkyScan1172, Kontich, Belgium), as described in previous studies 
(9,10).  The voltage and current of X-ray source were set at 70 kV and 141 µA, 
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respectively, with a pixel size of 8.6 µm and a 0.5 mm-thick aluminum filter was 
used.  The exposure time was 580 ms, and X-ray projections were obtained at 0.7 
intervals with a scanning angular rotation of 180, and 8 frames were averaged for 
each rotation.  To generate three-dimensional (3D) images, scans were 
reconstructed using the system-reconstruction software (NRecon; Skyscan).  
Sagittal sections were obtained using the Skyscan DataViewer software, then the 
linear distance from the cementoenamel junction (CEJ) to the alveolar bone crest 
(ABC) was measured in millimeters using the Skyscan CT-Analyzer software. For 
each sample, the linear distance was measured from two points: distopalatal of M1 
and mesiopalatal of M2.  Longer distance means more bone loss and vice versa.  
Coronal sections obtained using the Skyscan DataViewer were used to measure 
bone volume (BV), trabecular thickness (Tb.Th), trabecular number (Tb.N) and 
trabecular separation (Tb.Sp) using the CT Analyzer.  A rectangular region of 
interest (ROI, excluding the roots) was selected, with its length extended from the 
distopalatal of M1 to the mesiopalatal of M2, width from the palatal side to the 
midline of M1 and M2, and height 130 slices below CEJ of M1 and M2.  The sample 
analysis was performed by two examiners independently to ensure accurate 
assessment.  
2.2.8 Histological evaluation 
After completing the µ-CT analysis, all specimens were decalcified in 14% 
ethylenediaminetetraacetic acid (EDTA) solution for one month.  After 
decalcification, samples were embedded in paraffin.  Sagittal sections (5µm) were 
obtained in a mesiodistal direction with roots aligned in one plane and then stained 
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with hematoxylin and eosin for microscopic observation.  To evaluate connective 
tissues between M1 and M2 for inflammatory cell infiltrate and alveolar crest for 
osteoclasts, a pathologist (SML) who was blind to experimental groups 
qualitatively assessed samples using a light microscope (Olympus System 
Microscope Model BX53) under 200 magnification.  Neutrophils and lymphocytic 
infiltrate were evaluated qualitatively in the gingival tissues above the alveolar crest 
using a scoring system(20,21) (Table II).  Osteoclasts lining the surface of alveolar 
crest were also qualitative assessed using a scoring system(22) (Table III).   
 
2.2.9 Statistical analysis 
All the obtained data were presented as the mean ± standard deviation (SD).  
Statistical analysis was performed using SPSS 22.0 software (SPSS Inc., Chicago, 
IL, USA) and Prism 7.0 software (GraphPad, San Diego, CA).  Continous 
outcomes among more than three groups were compared using the one-way 
Analysis of Variance (ANOVA) for one variable data and two-way ANOVA for two 
variable data. Tukey’s post-hoc multiple comparisons was conducted in case a 
significant difference among the group means was found. P-value < 0.05 was 







        2.3.1 Aqueous solubility of SIM-PPi 
The aqueous solubility of SIM-PPi at 22 ± 2 C and pH 7 was analyzed and 
compared to SIM.  The solubility of SIM-PPi was determined to be 0.899 mg/mL 
(equivalent to 0.53 mg/mL of SIM) after being equilibrated for 48 hr in deionized 
water and 0.969 mg/mL (equivalent to 0.57 mg/mL of SIM) in phosphate buffer.  
For SIM, its solubility was determined to be 0.0025 mg/mL in deionized water and 
0.0073 mg/mL in phosphate buffer.  Clearly, conjugating PPi to SIM trimer has 
greatly improved SIM’s water solubility.  
 
2.3.2 SIM-PPi binding to hydroxyapatite (HA) 
HA binding assay was performed to assess the bone affinity of SIM-PPi (Fig. 1).  
After 30 min incubation, SIM-PPi showed significantly higher (23%) binding to HA 
when compared to SIM alone which did not show any binding.  As the HA 
incubation time extended to 2 hr, SIM-PPi’s binding to HA increased to 50% and 
reached the plateau.  After 6 hr of incubation, SIM-PPi’s binding to HA remained 
at 51%.  During the entire binding study, SIM exhibited minimum binding to HA.   
As a strong osteotropic agent and a positive control for the HA binding experiment, 





    2.3.3 Cell viability  
To evaluate the in vitro safety of SIM-PPi, both RAW264.7 and MC3T3-L1 cells 
were treated with wide range of concentrations of SIM-PPi (1 nM to 1mM, SIM 
equivalent) for 24, 48 and 72 hr and the cell viability was determined using the 
MTT assay (Figure 2).  For both cell lines, they almost shared the same toxicity 
profile.  The viability of RAW 264.7 cells treated with more than 100 µM of SIM-
PPi (SIM equivalent) was substantially decreased over the three days, the viability 
was less than 60% after 72 hr. The viability of MC3T3-L1 cells treated with more 
than 250 µM of SIM-PPi (SIM equivalent) was decreased dramatically after three 
days (less than 40%).  However, when both cell lines treated with more than 100 
nM of free SIM, the viability was reduced over the three days, indicating that SIM 
has narrower toxicity range than SIM-PPi. Free PPi increased cell populations and 
did not show any signs of toxicity for 72 hr.  Hence, 100 nM of SIM-PPi (SIM 
equivalent) was used in the following experiments as non-toxic concentration to 
evaluate both anti-inflammatory and osteogenic effects on macrophages RAW 
264.7 and osteoblasts MC3T3-L1, respectively.    
 
      2.3.4 Effect of SIM-PPi on LPS-induced cytokines 
The concentrations of IL-6 and IL-1β were detected in the culture supernatants of 
RAW 264.7 cells using ELISA kits (Fig. 3).  LPS challenged cells showed a 
tremendous increase in both cytokines comparing to the control group (medium 
only).  SIM-PPi treated group showed a significant reduction in IL-6 (P < 0.05) and 
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IL-1β (P < 0.0001) when compared to the LPS group.  The SIM-treated group 
exhibited the lowest concentration of both IL-6 and IL-1β. 
       2.3.5 ALP activity measurement 
The ALP activity in the control and experimental groups are shown in Figure 4B.  
The cells in the negative control culture did not show any significant activity of ALP 
after 3, 7, and 14 days, as expected.  As anticipated, in the positive control culture, 
the cells expression of ALP was increased significantly over 14 days.  Among all 
the tested samples, free SIM culture showed the highest level of ALP after 3, 7, 
and 14 days (P < 0.0001).  At day 7, ALP activity increased significantly for SIM-
PPi and PPi cultures compared to the negative control (P < 0.0001).  After 14 days, 
SIM-PPi culture continued to express a substantial level of ALP as compared to 
the negative control (P < 0.0001), while PPi culture showed a slight decrease in 
the ALP activity.       
 
       2.3.6 Alizarin red S (ARS) and von Kossa staining 
To evaluate calcium deposit and mineralized nodules, ARS and von Kossa 
staining assays were used.  As shown in Figure 4A&C, the two stains showed 
similar observations, and they were both in agreement with the ALP findings.  The 
negative control group showed very little calcium deposit and ARS quantity, while 
positive control and SIM treated groups exhibited significant ARS quantity (P < 
0.0001) with the highest mineralized nodules when compared to negative control 
(con-), as expected.  And most importantly, SIM-PPi treated group showed 
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significantly higher ARS quantity (P < 0.01) when compared to negative control 
and PPi groups, with more mineralized nodules formation.  PPi group has the 
lowest ARS quantity and calcium deposit among all tested groups except the 
negative control. 
 
       2.3.7 Micro-computed tomography (µ-CT) analysis 
As shown in Figure 5A, it is obvious that the SIM-PPi treated group preserved 
alveolar bone crest compared to other treated groups.  The linear distance of CEJ 
to ABC, representing alveolar crest height, indicated that the SIM-PPi treated 
group had significantly shorter distance when compared to saline-treated group 
(0.98 mm vs. 1.32 mm, P > 0.05).  SIM and PPi treated groups did not exhibit 
statistically significant differences when compared to the saline-treated group as 
presented in Figure 5B.  For further validation of alveolar bone loss, different bone 
volumetric parameters, as shown in Figure 6, were quantified.  The SIM-PPi 
treated group demonstrated significantly (P > 0.05) different values in bone volume 
(BV, 0.85 mm3 vs. 0.38 mm3), trabecular thickness (Tb.Th, 0.78 mm vs. 0.62 mm), 
trabecular number (Tb.N, 2.86 mm−1 vs. 1.69 mm−1) and trabecular separation 
(Tb.Sp, 0.35 mm vs. 0.47 mm) than the saline group.  In contrast, when comparing 
SIM and PPi treated groups to the saline group, none of the above parameters 





2.3.8 Histological evaluation  
To evaluate the effect of the different treatments on the inflammatory infiltrate and 
osteoclasts, H&E stained sections were assessed qualitatively.  Histology scores 
of neutrophils and lymphocytes were shown in Figure 7B-C, based on the grading 
criteria in Table II.  SIM-PPi treated group earned the lowest score of neutrophils 
(P < 0.01) and lymphocytes (P < 0.0001) when compared to saline group, while 
neutrophils of SIM-treated group did not exhibit statistically significant difference 
when compared to the saline group.  Osteoclast scores of the SIM-PPi-treated 
group were the lowest among all the treatment groups and were significantly lower 














2.4 DISCUSSION   
Simvastatin (SIM) has been reported to have osteogenic (7,8) and anti-
inflammatory properties (23,24), making it a promising candidate for therapeutic 
intervention for periodontal diseases. Local application of SIM has been explored 
in periodontitis treatment (25–28).  The lack of osteotropicity and its poor water 
solubility have limited the clinical applications of SIM in managing periodontitis.  To 
overcome these limitations, alternatives technologies for local delivery of SIM have 
been developed to enhance solubility and to provide a sustained release; and have 
shown potential protection of the periodontal tissues.  In a previous study, local 
application of SIM (0.5 mg)/alendronate-β-cyclodextrin complex (SIM–ALN–CD) 
was tested on an LPS-induced periodontitis as a preventative agent against a 
future episode of periodontitis.  It was concluded that the locally applied SIM–ALN–
CD has the potential to prevent periodontitis associated bone loss(10).  A concern 
with this formulation is the use of ALN (a bisphosphonate) as the bone-homing 
moiety.  It has been well recognized that the long-term clinical use of 
bisphosphonates has been associated with higher incident rates of osteonecrosis 
of the jaw (ONJ) and atypical fracture (29,30).  Another previous study aimed to 
examine the effect of a locally delivered SIM prodrug in a ligature-induced 
periodontitis rat model(9).  The amphiphilic macromolecular prodrug of SIM (1.5 
mg) was designed and prepared by conjugating SIM trimer to a polyethylene glycol 
monomethylether (mPEG) molecule.  The study concluded that three weekly 
injections of the macromolecular SIM prodrug (SIM-PEG) decreased alveolar bone 
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loss and inflammation in rats.  While the SIM-PEG design solubilizes SIM in water 
by forming micelles, a limitation of this prodrug is its lack of osteotropicity and the 
relatively low drug loading. 
 
To provide SIM with better water solubility and osteotropicity but also to avoid 
potential long-term side effects associated with bisphosphonates (e.g. ONJ), we 
have developed a novel SIM prodrug by conjugating SIM trimer directly to a 
pyrophosphate (PPi) (Scheme 1).  This design was built upon the findings of our 
previous studies(9,10).  The three SIMs are chemically conjugated via ester bonds 
which can be hydrolyzed in vivo in the presence of esterases.  One of the three 
SIMs conjugated to PPi is in the active SIM acid form, and the other two are in the 
lactone form, which would be activated upon exposure to the in vivo environment 
(e.g. esterase, water, low pH, and elevated temperature).  Pyrophosphate (PPi) is 
a water-soluble and calcium-binding molecule.  It is known for decades in the food 
industry as a leavening agent.  Due to its high affinity to enamel, dentin, and tarter 
(31), it has been used widely in dental and oral care products (32–34).  PPi is 
biodegradable (via phosphatase) with phosphate as its degradation product, which 
has a much better safety profile than the bisphosphonates (29,30).  Therefore, we 
proposed to conjugate PPi to SIM-trimer to improve SIM’s water solubility and to 
provide osteotropicity.  The findings of the present study validate these design 
objectives and confirm the anti-inflammatory and periodontal bone 
preservation/regeneration capacity of the SIM-PPi design on an experimental 
periodontitis rat model.  
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Conjugating PPi to SIM trimer increased its water solubility over 200-fold.  The 
binding experiment (Figure 1) showed that SIM-PPi has stronger binding to HA 
than free SIM, confirming that SIM-PPi as a bone-specific prodrug is a viable 
strategy for local delivery of SIM to the skeletal tissues.  In Raw 264.7 culture, SIM-
PPi was found to effectively inhibited LPS-induced interleukin-1β (IL-1β), which is 
considered as one of the most potent inducers of bone resorption, and interleukin-
6 (IL-6), which is secreted in response to bone resorbing inducers including IL-
1β(35).  These findings suggest that SIM-PPi may reduce periodontal inflammation 
by attenuating the pro-inflammatory cytokines secreted by the inflammatory cells.  
The data also showed that SIM-PPi could significantly increase ALP activity in 
MC3T3-E1 culture after 7 and 14 days when compared to negative control (Figure 
4B).  In addition, ARS and Von Kossa staining data indicated that SIM-PPi 
significantly increased calcium deposits and mineralized nodules formation in 
MC3T3-E1 when compared to negative control (Figure 4A&C).  Taken together, 
these in vitro data confirm that SIM-PPi retains the well-established SIM-mediated 
anti-inflammatory (23,24) and osteoinductive (36) activities after conjugating with 
PPi.  It is important to note that due to its prodrug nature, SIM-PPi showed lower 
in vitro activity than SIM (SIM-PPi needs to be activated by exposing to an in vivo 
inflammatory condition: esterase, acidic pH, and elevated temperature). 
When evaluated in vivo using a ligature-induced periodontitis rat model, micro-CT 
analysis of alveolar bone showed that the SIM-PPi treatment was the most 
effective treatment among all groups in preserving alveolar bone integrity (Figures 
5&6).  It significantly prevented alveolar crest loss (Figure 5) and maintained bone 
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volumetric parameters (BV, Tb.Th, Tb.N, and Tb.Sp) (Figure 6) when compared to 
saline control.  Also, in accordance with the micro-CT findings, histological 
evaluation revealed a superior anti-inflammatory effect of SIM-PPi.  It significantly 
reduced both inflammatory cell infiltrate (neutrophil and lymphocyte) and 
osteoclast score when compared to control (Figure 7).  PPi itself did not show any 
significant protective effects against bone loss indicating that it did not contribute 
to preserving alveolar bone integrity.  Ideally, a local treatment for periodontal bone 
loss should be given when developing periodontitis lesions are identified.  
Therefore, to make the treatment more clinically relevant, the weekly SIM-PPi 
injections was initiated at the time of ligature placement and continued for 3 weeks.   
Overall, the weekly administration of SIM-PPi was found to be more effective in 
preventing periodontitis-induced alveolar bone loss when compared to dose 
equivalent SIM treatment.  We believe that SIM-PPi’s retention after local 
administration in combination with its gradual activation and releasing of 
simvastatin acid provide a rational explanation of the superior therapeutic effect of 
SIM-PPi over free SIM in prevention of alveolar bone loss associated with 
periodontitis.  Furthermore, the weekly SIM-PPi administration schedule, possibly 
using pocket irrigation, would be easily adapted into current dental preventive care 








In this study, we report the design and synthesis of a novel osteotropic simvastatin 
(SIM) prodrug by conjugating three SIMs to a pyrophosphate (PPi).  This prodrug 
design not only enhanced SIM solubility but also exhibited affinity to hydroxyapatite 
(HA), with retained bone anabolic and anti-inflammatory properties of SIM.  When 
tested on an experimental periodontitis rat model, SIM-PPi was found to be 
effective in preserving periodontal bone.  Upon further optimization, we believe this 
novel simvastatin prodrug may have the potential to be developed into a novel 
















Table I. In vivo experimental design.  
 
*Doses: SIM-PPi (2.56 mg, equiv. 1.5mg SIM), SIM acid (1.56mg, equiv. 1.5mg 









Group Number Side Week 1* Week 2* Week 3* Week 4 
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0 Normal (no inflammatory cells). 
 
1 Few inflammatory cells (lining < 30 % of the affected tissues above 
the alveolar crest and between M1 & M2). 
 
2 Some inflammatory cells (lining 30 - 60 % of the affected tissues 
above the alveolar crest and between M1 & M2). 
 
3 Many inflammatory cells (lining > 60 % of the affected tissues above 














0 Normal (no osteoclasts). 
1 Few osteoclasts (lining < 5% of most affected alveolar bone 
surface). 
 
2 Some osteoclasts (lining 5 - 25% of most affected alveolar bone 
surface). 
 
































































































































Figure 1.  Quantitative assessment of hydroxyapatite (HA) binding of SIM-PPi with 
varying length of incubation time: 0.5, 2, and 6 hr. Alendronate (ALN) and free 
simvastatin (SIM) were used as a positive and negative controls, respectively. 











Figure 2.  Effect of different concentrations of SIM-PPi, SIM, and PPi on growth of 
(A) Raw 264.7 cells and (B) MC3T3-E1 cells measured by MTT assay following 













Figure 3.  The impact of SIM (100 nM), PPi, and SIM-PPi (equivalent dose) on 
LPS-induced IL-1β and IL-6 secretion in RAW 264.7 cells. Mean cytokine 
concentrations are shown ± SD.  *p< 0.05, **p< 0.01, ***p<0.001, and ****p< 0.0001 










Figure 4. The in vitro evaluation of SIM-PPi’s osteogenic efficacy using MC3T3-
E1 cell line. (A) Representative images of Alizarin Red S (ARS) and von Kossa 
stained wells after 28 days of culture in a 24-well plate with SIM, PPi, and SIM-PPi 
treatments. (B) Alkaline phosphatase (ALP) activity of MC3T3-E1 cell line treated 
with 100 nM dose equivalent of SIM, PPi, and SIM-PPi.  ALP was measured after 
3, 7, and 14 days of culture.  The values are shown as mean ± SD.  #p< 0.0001 
when compared to negative control (two-way ANOVA with  
Dunnett's multiple comparisons). (C) ARS quantification measured at 405 nm.  
*p<0.05, ***p<0.001, ****p<0.0001. #bp<0.01 and #dp<0.0001 when compared to 
negative control group. +ap<0.05, +bp<0.01, and +cp<0.001 when compared to 




Figure 5. The in vivo evaluation of SIM-PPi efficacy in experimental periodontitis 
rat model.  (A) Micro-CT sagittal images showing the effect of different treatments 
on the maxilla of cementoenamel junction (CEJ) to alveolar bone crest (ABC).  
White arrows indicate ABC-CEJ distance. (B) Measurement of the linear distance 
between cementoenamel junction (CEJ) and alveolar bone crest (ABC).  Values 





Figure 6.  Micro-CT analysis of alveolar bone quality after different treatments. 
Bone volume (BV), trabecular thickness (Tb.Th), trabecular number (Th.N), and 
trabecular separation (Tb.Sp).  Values are presented as the mean ± SD.  *p< 0.05 







Figure 7. Histological analysis of papillary connective tissue and alveolar bone 
between first molar (M1) and second molar (M2) after 3 weeks of different 
treatments.  (A) Representative images from different treatment groups of H&E 
stained sections of connective tissue above the alveolar bone crest (ABC) and 
between first molar (M1) and second molar (M2).  Black arrows indicate alveolar 
bone crest.  (B-C) Qualitative assessment of neutrophil and lymphocytic 
infiltrate interproximally between first molar (M1) and second molar (M2).  Scoring 
criteria is shown in Table II, *p< 0.05, **p< 0.01, and ****p<0.0001 (one-way 
ANOVA).  (D) Qualitative assessment of osteoclasts lining the surface of alveolar 
bone crest.  Scoring criteria is shown in Table III, *p< 0.05 (one-way ANOVA with 
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As mentioned in Chapters 1&2, simultaneous anti-inflammatory and 
osteogenic intervention is essential for periodontitis management. In this chapter, 
glycogen synthase kinase 3 beta (GSK3β), a multi-tasking serine/threonine kinase 
with crucial roles in several physiological processes including inflammation and 
bone homeostasis, was selected.  It has been shown to have a critical role in host 
inflammatory response(1–3) and bone homeostasis(4) as a negative regulator, 
suggesting that inhibitors of GSK3β may provide therapeutic effects for 
inflammatory and bone metabolic diseases(5). Particularly, a GSK3β inhibitor 
(SB216763) has been studied in periodontal disease and data confirmed its 
therapeutic benefits in preventing alveolar bone loss associated with periodontal 
disease(6).  During the last decade, several selective GSK-3β inhibitors have been 
synthesized and tested in clinical trials at various phases(7,8).  In particular, 6-
bromoindirubin-3’-oxime (BIO), a potent GSK3β inhibitor with an enzymatic IC50 of 
5 nM, has exhibited anti-inflammatory and strong bone and teeth anabolic 
effects(2,3,9–15).  However, due to the involvement of GSK3 in many other 
physiological processes, systemic administration may cause serious adverse side 
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effects(16–18).  Hence, it is necessary to limit and restrict its biological action 
primarily at the intended site of action.  Local delivery of BIO into the periodontal 
pocket allows to directly target periodontal tissue, achieving high local 
concentrations along with minimizing systemic toxicities.  However, BIO’s poor 
aqueous solubility and rapid clearance from periodontal pockets are major 
challenges.   
 
Thermoresponsive hydrogel formulations injected into the periodontal 
pocket would be a promising option for the local delivery of BIO to augment the 
bony defect associated with periodontitis.  Poloxamer 407 (Pluronic F127), an 
excipient of various formulations that is approved by U.S. FDA for pharmaceutical 
applications, is a triblock amphiphilic copolymer consisting of blocks of ethylene 
oxide and propylene oxide (PEO101 PPO56 POE101)(19–22).  It has been used 
extensively in controlled drug and cell delivery (23).  Its unique thermal reversible 
gelation property in aqueous solutions (in the range of 20–35%  w/v) makes it an 
attractive biomaterial for regenerative applications in dentistry and other 
areas(24,25).  The amphiphilic F127 polymer enhances the solubility of 
hydrophobic drugs at room temperature by forming micelles. When exposed to 
physiological temperature, the polymer solution forms hydrogel, holding 
encapsulated drugs in its collapsed micellar structure to provide sustained release 
kinetics.  F127 is also known to be non-toxic and biocompatible (25).  The constant 
flow of crevicular fluid, the poor bone-adhesion and mechanical properties of F127 
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hydrogel, however, would significantly limit the bioavailability of the payload drug 
in the periodontal pocket.  
 
Therefore, to improve binding of F127 hydrogel to the hard tissues, we here 
report the development of a novel thermosensitive pyrophosphorolated F127 
hydrogel system (PF127) for the delivery of BIO.  After detailed characterization, 
the therapeutic potential of the BIO-loaded PF127 delivery system was evaluated 
on experimental periodontitis rat model. 
 
3.2 METHODS AND MATERIALS 
3.2.1 Materials and Reagents 
Pluronic F127 and pyrophosphate were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). BIO was synthesized according to literature(26)  Dense Ceramic 
Hydroxyapatite discs (0.5" diameter and .08" Thick) were purchased from Clarkson 
Chromatography Products, Inc. (South Williamsport, PA USA).  Mouse osteoblast 
MC3T3-L1 cells were originally purchased from ATCC (Manassas, VA, USA).  
Minimum Essential Media (alpha-MEM) and trypsin-EDTA were purchased 
from Gibco (Grand Island, NY, USA).  Fetal bovine serum (FBS) was obtained 
from Gemini BenchMark (West Sacramento, CA).  Cell Counting Kit-8 (CCK-8) 
was purchased from Dojindo Molecular Technologies, Inc. (Rockville, MD USA).  
All other reagents and solvents, if not specified, were obtained from either Fisher 




3.2.2 Synthesis of Pyrophosphorolated Pluronic F127 (F127-PPi) 
Synthesis of Tosylated Pluronic F127 
Pluronic F127 (1.0 g, 0.079 mmol) and 4-toluenesulfonyl chloride (151 mg, 0.79 
mmol) were dissolved in dry dichloromethane, followed by the addition of pyridine 
(62 μL, 0.79 mmol) and the solution was stirred for 24 hours.  Dichloromethane 
(100 mL) was then added.  The resulting solution was washed with HCl solution (1 
M, 20 mL), brine (100 mL × 2) and water (100 mL × 2).  The organic phase was 
separated and dried over MgSO4.  After removal of the solvent, the residue was 
purified on a LH-20 column to give 922 mg of the desired product, yield: 90%. 
1HNMR (CDCl3, 500 MHz) δ ppm 7.78 (d, J = 3.0 Hz, 1H), 7.33 (d, J = 3.0 Hz 1H), 
4.14 (t, J = 5.0 Hz, 2H), 3.77 (t, J = 4.5 Hz, 8H), 3.59-3.55 (m, 872 H), 3.50-3.44 
(m, 142 H), 3.38 (m, 65H), 2.44 (s, 3H), 1.12 (t, J = 5.0 Hz, 195H); 13C NMR (CDCl3, 
125 MHz) δ ppm 144.7, 133.0, 129.8, 127.9 , 75.5, 75.4, 75.1, 73.4, 73.0, 72.9, 
72.7, 69.2, 68.7, 21.6, 17.5, 17.3. 
Synthesis of Pyrophosphorolated Pluronic F127 
The tosylated Pluronic F127 (1.0 g, 0.077 mmol) and tris(tetra-n-butylammonium) 
hydrogen diphosphate [(n-Bu4N)3(HO)P2O6] (0.31 mmol, 280 mg)were dissolved 
in dry acetonitrile, the solution was stirring at room temperature for 3 hours until 
the starting materials completely disappeared (monitored by TLC).  After 
evaporation of the solvents, the residue was dissolved in water (10 mL).  The 
solution was dialyzed (MWCO = 10 kDa) against NaCl solution (0.1 mol/L) 
overnight to exchange tetrabutyl ammonium to sodium, after which the solution 
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was further dialyzed against distilled water to remove the excessive NaCl.  The 
final aqueous solution was lyophilized to obtain 859 mg of final pyrophosphorolated 
Pluronic F127 product, yield: 85%. 1HNMR (CDCl3, 500 MHz) δ ppm 4.16 (t, J = 
5.0 Hz, 2H), 3.78 (t, J = 4.5 Hz, 8H), 3.59-3.54 (m, 872H), 3.50-3.44 (m, 142 H), 
3.39-3.36 (m, 65H), 2.44 (s, 3H), 1.13 (t, J = 5.0 Hz, 195H); 13C NMR (CDCl3, 125 
MHz)  δ ppm 75.5, 75.4, 75.1, 73.4, 73.0, 72.9, 72.8, 72.7, 70.6, 17.5, 17.3; 31P 
NMR (202.5MHz, CDCl3):  (ppm) = -7.70 (d, J = 20.2Hz), -7.91 (d, J = 20.2Hz). 
 
3.2.3 Preparation of BIO-loaded Thermoresponsive Hydrogel  
PF127 hydrogel formulations with predetermined polymer concentrations (20, 25 
and 30% w/v) were prepared by mixing F127-PPi and F127 at different ratio (0:100, 
25:75, 50:50, 75:25, 100:0% w/w).  In brief, the desired amount of F127-PPi and 
F127 was dissolved in phosphate buffered saline (PBS, pH 7.4) with stirring in an 
ice-water bath (~ 4 °C, to avoid micellization and/or gelation during solution 
preparation) until clear solution (PF127) was obtained and then stored at 4 °C 
overnight.  BIO was then dissolved in the polymer solutions by continuous stirring 
at 4 °C, the obtained solutions were filtered through 0.8 µm filter syringes.  
 
 
3.2.4 In vitro Hydroxyapatite (HA) Binding 
To predict the binding of formulated hydrogels to HA, which is the primary inorganic 
component of natural hard tissues, an in vitro binding test was performed using HA 
discs.  Briefly, polymer solutions (25% w/v) were prepared, containing 100 µM of 
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BIO, with different ratio of F127-PPi and F127 (0:100, 25:75, 50:50, 75:25, and 
100:0% w/w) to optimize binding affinity. Hydrogels (1 ml) were formed on HA disc 
placed in plastic wells at 37 °C, and allow hydrogels to stabilize for 15 min.  After 
that, HA discs, on which hydrogels are formed, were inverted with temperature 
maintained at 37 °C by keeping the inverted hydrogels inside the bath.  The binding 
time of hydrogel to HA disc was measured.  The binding experiment was 
performed in triplicate. Based on this study, one formulation was selected for all 
subsequent experiments. 
 
3.2.5 Biocompatibility of PF127 Hydrogel 
To measure cell viability of selected PF127 hydrogel formulation (25% w/v of mixed 
F127-PPi and F127, 50:50% w/w) comparing to F127 hydrogel (25% w/v) with or 
without BIO (100 nM), Cell Counting Kit-8 (CCK-8) was utilized.  Briefly, mouse 
preosteoblast MC3T3-L1 cell line was cultured in Minimum Essential Media (alpha-
MEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (basal growth medium).  Cells were incubated at 37 °C in 
5% CO2 to 90% confluence.  The hydrogels were extracted in alpha-MEM and then 
incubated at 37 ◦C for 24 h, according to the ISO Standard 10993–12(27,28).  Cells 
were then seeded in 96 well plates (1 × 104 cells/well) and incubated for 24 h.  
Subsequently, cells were treated with either media only, PF127 extract, PF127-
BIO extract, F127 extract, F127-BIO extract, or free BIO (100 nM), and then the 
plates were incubated for 24 and 48 h.  Following each time point, 10 μL of CCK-
8 reagent was then added to each well and further incubated for 4 h at 37 °C.  The 
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absorbance of each well was recorded at 450 nm using a microplate reader 
(SpectraMaxM2, Molecular Devices, Sunnyvale, CA, USA). 
 
3.2.6 Comparing Aqueous Solubility of BIO in PF127 vs F127 
This experiment was conducted to measure the aqueous solubility of BIO in PF127 
solutions comparing to F127.  The solubility values of BIO were obtained by 
measuring equilibrium solubility after adding the analyte to the testing medium for 
a predetermined period of time as reported previously(29).  Briefly, an excessive 
amount of BIO was added to different concentrations of either PF127 or F127 
solutions in microcentrifuge tubes.  The suspensions were agitated on a rotor at 4 
C for 48 h to reach the equilibrium.  The mixtures were then centrifuged (2,000 
rpm, 5 min, at 4 C) to settle the undissolved drug.  The supernatants (saturated 
solutions) were obtained by filtering through 0.2 µm syringe filters, and then the 
BIO concentrations were measured using a UV spectrophotometer (SpectraMax 




3.2.7 Gelation and Viscosity Studies  
To investigate sol-gel-sol phase transition behavior of PF127 solutions with or 
without BIO comparing to F127 solutions, phase transition diagrams were 
constructed using the tube inverting method(25,30,31).  Each solution at a given 
concentration ranging between 20 and 40% w/v was prepared as described above.  
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A sample volume of 1 mL was transferred into an Eppendorf tube and then 
subjected to a controlled temperature increase from 4 to 80 °C.  Each 1 °C increase 
was followed by isothermal maintenance for 5 minutes and then inverting the tube 
for visual inspection of the occurrence of phase transition. The sol and gel phases 
were identified as “flowing” and “non-flowing”, respectively.  The gelation time of 
PF127 and F127 solutions at physiological temperature was also determined by 
incubation at 37 °C followed by tube inversion every 5s.  The viscous properties of 
gel phase were also investigated at constant temperature by means of flow 
curves(25) (37 °C, shear rate from 1 to 100 s-1) using a rheometer (TA Instruments 
AR1500ex). Samples were poured on the rheometer lower plate at 0 °C, heated to 
37°C and maintained for 15 minutes to reach the thermal stability before 
isothermally tested. 
 
3.2.8 In vitro Release of BIO from Hydrogel  
The release rate of the physically entrapped BIO from PF127 hydrogels (20, 25, 
and 30% w/v), was studied by a membrane-less experiment, as reported 
previously(27,28,32).  Briefly, samples of 1 mL of polymer solutions containing 0.5 
mg of BIO were transferred into screw cap-tubes and incubated in a water bath at 
37 °C until the gels were formed.  After gelation, 2 mL of phosphate buffered saline 
(PBS; pH 7.4) containing 0.5 % tween 80 pre-equilibrated at 37 °C was gently laid 
over the surface of the hydrogels and incubated in a water bath at 37 °C with 
continuous gentle shaking. To measure the release of BIO, release medium (2 mL) 
were taken at regular time intervals and replaced with an equal volume of pre-
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equilibrated fresh release buffer.  The concentration of BIO was determined by 
measuring the absorbance at 260 nm using a UV spectrophotometer (SpectraMax 
M2, Molecular Devices, Sunnyvale, CA, USA).  Release study was performed in 
triplicate. 
 
3.2.9 In vitro Hydrogel Erosion  
The erosion time of PF127 hydrogel formulations (20, 25, and 30% w/v) was 
determined by performing the weight remaining (%) experiment, as reported by 
other studies(27,28,32).  Briefly, samples of 1 mL of polymer solutions were 
transferred into screw cap-tubes and incubated in a water bath at 37 °C until the 
gels were formed.  After gelation, the original weight of the hydrogel samples was 
measured as (W0).  Subsequently, 2 mL of PBS (pH 7.4) pre-equilibrated at 37 °C 
was gently laid over the surface of the hydrogels and incubated in a water bath at 
37 °C with continuous gentle shaking.  The weight of remaining hydrogels (Wt) was 
measured at regular time intervals after completely blotting off the buffer.  Erosion 
study was performed in triplicate. Weight remaining (%) was calculated as:  







3.2.10 Evaluation of BIO Hydrogel’s Therapeutic Efficacy on an Experimental 
Periodontitis Rat Model  
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Sprague Dawley rats (female, 10-month-old, retired breeders) were purchased 
from Envigo.  The animals were acclimated for one week prior to any experimental 
procedure.  Rats were divided randomly into six groups: Healthy control, 
experimental periodontitis (EP) treated with saline, EP treated with 25% w/v of 
mixed F127-PPi and F127 hydrogel (50:50% w/w, containing 100 µM of BIO) 
(PF127-BIO), EP treated with 25% w/v of F127 hydrogel (containing 100 µM of 
BIO) (F127-BIO), EP treated with 25% w/v of PF127 hydrogel, and EP treated with 
free BIO (100 µM).  Silk ligatures were used to induce the experimental 
periodontitis as previously described(29,33).  Briefly, each rat was anesthetized 
using a chamber attached to isoflurane vaporizer (1- 4% isoflurane and 100% 
oxygen), followed by body weight measurement.  To maintain anesthesia during 
experimental procedures, a nose cone (0.5% - 2% isoflurane and 100% oxygen) 
was applied throughout the entire experimental procedure.  Experimental 
periodontitis was induced in all groups by gently tightening a 4-0 silk ligature 
around the maxillary 2nd molars on both sides.  After one week, ligatures were 
removed.  Treatments were locally injected (10µL) into the palatal gingiva between 
the maxillary first molar (M1) and second molar (M2) on the first day of week 1, 2 
and 3 after ligature placement.  At week 4, all animals were euthanized using CO2 
asphyxiation, followed by dissecting the entire palate including all three molars and 
fixation in 10% formalin for µ-CT and histological evaluations.  All animal 
procedures were approved by the Institutional Animal Care and Use Committee 




3.2.11 Micro-computed Tomography (µ-CT) Analysis  
All palate samples (including all three molars) were scanned using a micro-CT 
imaging system (Bruker SkyScan1172, Kontich, Belgium), as described in 
previous studies (34).  The voltage and current of X-ray source were set at 70 kV 
and 141 µA, respectively, with a pixel size of 12.9 µm and a 0.5 mm-thick aluminum 
filter was used.  The exposure time was 1880 ms, and X-ray projections were 
obtained at 0.7 intervals with a scanning angular rotation of 180, and 5 frames 
were averaged for each rotation.  To generate three-dimensional (3D) images, 
scans were reconstructed using the system-reconstruction software (NRecon; 
Skyscan).   Sagittal sections were obtained using the Skyscan DataViewer 
software, then the linear distance from the cementoenamel junction (CEJ) to the 
alveolar bone crest (ABC) was measured s using the Skyscan CT-Analyzer 
software.  For each sample, the linear distance was measured from two points: 
distopalatal of M1 and mesiopalatal of M2.  Longer distance means more bone 
loss and vice versa.  Coronal sections obtained using the Skyscan DataViewer 
were used to measure bone volume (BV) and trabecular thickness (Tb.Th) using 
the CT Analyzer.  A rectangular region of interest between M1 and M2 was 
selected, with its length extended from the distopalatal of M1 to the mesiopalatal 
of M2, width from the palatal side to the buccal side of M1 and M2, and height 130 
slices below CEJ of M1 and M2.  Femurs were also collected and scanned to 
evaluate the systemic effect of BIO.  The scanning parameters were set as follows: 
voltage 70 kV, current 141 μA, exposure time 700 ms, resolution 8.6 μm, and 
aluminum filter 0.5 mm.  3D reconstructions were achieved using the NRecon and 
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DataViewer software.  A consistent polygonal region of interest of trabecular bone 
at the distal femur, from 20 slices to 100 slices proximal to the growth plate, was 
selected for bone quality analysis.  The mean bone mineral density (BMD), bone 
volume (BV), bone volume /tissue volume (BV/TV) and trabecular thickness 
(Tb.Th) were quantified using the CTAn software(35).  
 
3.2.12 Histological Evaluation 
After completing the µ-CT analysis, palates were decalcified in 14% 
ethylenediaminetetraacetic acid (EDTA) solution for two weeks.  The 
decalcification solution was changed every 3 days.   After decalcification, samples 
were embedded in paraffin.  Sagittal sections (4µm) were obtained in a mesiodistal 
direction with roots aligned in one plane and then stained with hematoxylin and 
eosin for microscopic observation.  To evaluate connective tissues between M1 
and M2 for inflammatory cells and alveolar crest for osteoclasts, a pathologist 
(SML) who was blind to experimental groups, semi-quantitatively assessed 
samples using a light microscope (Olympus System Microscope Model BX53) 
under 200 magnification.  The inflammatory cells were evaluated semi-
quantitatively in the gingival tissues above the alveolar crest using a scoring 
system(29,36,37), where 0 is negative, 1 is a few inflammatory cells lining less 
than 30 % of the affected tissues, 2 is some inflammatory cells (30 - 60 %), and 3 
is many inflammatory cells (>60 %).  Osteoclasts lining the surface of alveolar crest 
were also semi-quantitative assessed using a scoring system(29,38) where 0 is 
negative, 1 is a few osteoclasts lining less than 5% of most affected alveolar bone 
105 
 
surface, 2 is some osteoclasts (5 - 25%), and 3 is many osteoclasts (25 - 50%).  
Immunohistochemical staining of β-catenin was also performed using primary 
antibody (rabbit monoclonal anti-β-catenin antibody, Abcam, ab32572; 1:400 
dilution). After deparaffinization and rehydration, sections were incubated in citrate 
buffer (pH 6.0, 0.1 M) for antigen retrieval, washed, and then incubated in 
hydrogen peroxide.  Sections were then blocked and incubated with the primary 
antibody, followed by incubation with the secondary antibody.  The antibody 
complexes were visualized using the DAB chromogen.  Hematoxylin was used for 
counterstaining.  The staining intensity was independently evaluated by a 
pathologist (S.M.L.) using a scale of from 0 to 3, where 0 is negative, 1 is weak 
staining, 2 is moderate staining, and 3 is strong staining(14,39).  To calibrate 
SML’s scoring, another researcher (YA) independently scored a stack of slides and 
compared with SML’s results before SML proceeded with all the analyses. 
 
3.2.13 Statistical Analysis  
All the obtained data were presented as the mean ± standard deviation (SD).  
Statistical analysis was performed using Prism 8.0 software (GraphPad, San 
Diego, CA).  Continuous outcomes among more than three groups were compared 
using the Analysis of Variance (ANOVA).  Tukey’s post hoc t-test for multiple 
comparisons was used for the pairwise comparison.  P-value < 0.05 was 





3.3.1 In vitro Hydroxyapatite (HA) Binding 
HA binding study was performed to predict the bone affinity of the 25% w/v PF127 
hydrogel composed of different ratio of F127-PPi and F127 (Fig. 9a).  The binding 
time increased as the F127-PPi content was increased in the hydrogel.  Among 
different ratios of F127-PPi, 50, 75, and 100 (w/w %) showed the longest binding 
time to HA disc (24.6, 25.6, and 28.2 min), respectively. Their binding time was 
statistically significant when compared to F127 hydrogel (P < 0.0001). Also, the 
ratio of 25 (w/w %) exhibited considerable binding time (18.2 min) which was 
significantly higher than F127 hydrogel (P < 0.0017).  F127 hydrogel had the lowest 
binding time (8.5 min) among all the formulations.  Based on this observation, the 
formulation of 50:50% w/w ratio of PF127 and F127 was used in the subsequent 
experiments as showed strong binding affinity with relatively low PPi content. 
 
3.3.2 Biocompatibility of PF127-based Hydrogel 
To evaluate the in vitro safety of PF127 hydrogel comparing to F127 which is 
known to be biocompatible, MC3T3-L1 cells were treated with extracted PF127, 
PF127-BIO, F127, F127-BIO, or free BIO (100 nM) for 24 and 48 h, and the cell 
viability was determined using the CCK-8 assay (Fig. 8a-b).  The viability 
percentage of MC3T3-L1 cells treated with PF127 25% w/v, when compared to 
media-treated control, was slightly reduced to 84.5% after 24 h and further 
decreased to 79.5% after 48 h.  Whereas viability with F127 was 87.5% and 83.5% 
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after 24 and 48 h, respectively.  When BIO was added to hydrogels, cell viability 
was not changed significantly.  However, when cells treated with 100 nM of free 
BIO, the viability was improved to 102% and 104.5% comparing to media-treated 
control.  
 
3.3.3 Solubility of BIO in PF127 vs F127 
The saturated solubility of BIO in different concentrations of PF127 at 4 C and pH 
7 was analyzed and compared to its solubility in F127 (Fig. 9b).  The solubility of 
BIO appears to be proportionally dependent on polymer concentration.  In 20% 
PF127, its solubility was determined to be 0.5 mg/mL versus 0.1 mg/mL in 20% 
F127. However, when polymer concentration was increased to 25%, BIO’s 
solubility in PF127 was improved significantly to 2 mg/mL, while in F127 improved 
only to 0.3 mg/mL. When concentration further increased to 30%, solubility in 
PF127 was continued to increase to 3 mg/mL, while in F127 improved to 0.6 
mg/mL. Clearly, PF127 has greatly improved BIO’s aqueous solubility.  
 
3.3.4 Gelation and Viscosity Analysis of the PF127 Hydrogel  
Tube-inverting test was performed on PF127 solutions with or without BIO to 
determine their phase transition temperatures, in comparison to F127 solutions. 
Figure 10a shows the phase diagram of PF127.  Overall, lower critical gelation 
temperature (LCGT) of PF127 was lower than that of the F127 hydrogels, and 
upper critical gelation temperature (UCGT) of PF127 was higher than that of F127.  
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The addition of BIO into both PF127 and F127 hydrogels will not affect LCGT, but 
slightly increase UCGT.  Though all formulations underwent gelation within less 
than 2 minutes at 37 °C, PF127 formulations gelled faster than F127 with or without 
drug loading. Rheological tests were also performed on PF127 and F127 
hydrogels with and without BIO at 37 °C to study the effect of the 
pyrophosphorolation and drug content on their viscous property (Fig. 10b-c). All 
hydrogels showed a typical shear-thinning behavior (non-Newtonian) and the 
viscosity was decreased as a function of shear rate.  No notable differences in 
viscosity were observed between PF127 and F127 hydrogels within the same 
concentration, except 20% w/v PF127 which showed low viscosity and a very weak 





3.3.5 In vitro Release of BIO from PF127 Hydrogel  
BIO was physically entrapped inside the hydrogel matrix, and its release at 37 °C 
from PF127 hydrogels (20, 25, and 30% w/v) was studied.  As shown in Figure 9c, 
the release profiles of BIO from the hydrogels were shown to be a function of the 
concentration of hydrogel: the higher the hydrogel concentration, the slower the 
release rate.  The total release (~ 99 %) of BIO from 20% w/v hydrogel occurred 
in 24 h with burst release (~ 50%) in the first 3 h.  BIO release from 25% w/v 
hydrogel was shown with a burst release in the first 12 h followed by a sustained 
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release in the next 48 h.  While 30% w/v hydrogel exhibited sustained release of 
BIO over 48 h.  
 
 
3.3.6 In vitro Hydrogel Erosion  
The PF127 hydrogels erosion behavior was characterized by measuring weight 
remaining (%) at regular incubation time intervals.  The results correlate with the 
release study and shown to be a function of the concentration of hydrogel.  As 
shown in Figure 9d, 20% w/v hydrogel was completed eroded in 24 h, ~50% was 
eroded in the first 3 h.  While 25% w/v hydrogel was completed eroded in 48 h, 
~60% weight loss was observed in the first 6 h (burst erosion) followed by 





3.3.7 Micro-computed Tomography (µ-CT) Analysis 
As shown in Figure 11a, it is obvious that the PF127-BIO hydrogel treated group 
preserved alveolar bone crest compared to other treated groups.  The linear 
distance of CEJ to ABC, representing alveolar crest height, indicated that the 
PF127-BIO hydrogel treated group had a significantly shorter distance when 
compared to all other treated groups.  While F127-BIO treated group exhibited 
statistically significant difference only when compared to the saline-treated group; 
free BIO treated group did not show a statistically significant difference when 
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compared to the saline-treated group as presented in Figure 11b.  For further 
validation of alveolar bone loss, bone volume (BV, Figure 11c) and trabecular 
thickness (Tb.Th, Figure 11d) were quantified.  The value of BV for the PF127-BIO 
treated group was significant when compared to all the other treated groups.  In 
contrast, F127-BIO treated group exhibited a statistically significant difference only 
when compared to the saline-treated group.  The values of Th.Th for the PF127-
BIO and F127-BIO treated groups were significant when compared only to the 
saline-treated group.  Free BIO treated group when compared to the saline group, 
none of the above parameters produced a statistically significant difference.  
Femur analyses data did not show any significant difference between all groups. 
 
3.3.8 Histological Evaluation 
To evaluate the effect of the different treatments on inflammatory cells, 
osteoclasts, and β-catenin, stained sections were assessed semi-quantitatively.  
Histology scores of inflammatory cells were shown in Figure 12c.  PF127-BIO 
hydrogel-treated group has the lowest score of inflammatory cells when compared 
to all other treated groups (P < 0.0001 compared to saline, P < 0.01 compared to 
F127-BIO and free BIO trated groups), while F127-BIO and free BIO treated 
groups exhibited a statistically significant difference (P < 0.01) only when 
compared to the saline-treated group.  Osteoclast score of the PF127-BIO 
hydrogel treated group was the lowest among all the treatment groups and was 
significantly (P < 0.001) lower than the saline-treated group (Fig. 12d).  Scores of 
F127-BIO and free BIO treated groups were significant when compared to the 
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saline-treated group.  β-catenin positive cell score of the PF127 hydrogel-treated 
group was the highest among all the treatment groups (Fig. 12e, P < 0.0001 
compared to saline, P < 0.05 compared to F127-BIO and free BIO trated groups).  
Scores of F127-BIO and free BIO-treated groups were not significant (P > 0.05) 




Inflammation-induced alveolar bone loss in response to periodontal infection has 
long been the focus in clinical management of periodontal disease.  To prevent 
disease progression, simultaneous anti-inflammatory and osteogenic interventions 
are considered to be essential.  Glycogen synthase kinase 3 (GSK3) plays a 
substantial role in regulating the production of pro- and anti-inflammatory cytokines 
in innate and adaptive immune cells(1).  It acts as a downstream effector molecule 
in the PI3K pathway that stimulates the production of proinflammatory cytokines 
including TNF, IL-6, IL-12, and IL-1β, known to promote osteoclastogenesis and 
promote alveolar bone loss(6). GSK3 is also a cytosolic Wnt signaling inhibitor that 
induces β-catenin degradation and thus suppresses osteoblast 
differentiation(4,9,12,40).  Hence, there is a strong rationale for considering GSK3 
as an attractive therapeutic target for periodontal disease.  Pharmacological 
inhibition of GSK3 using 6-bromoindirubin-3’-oxime (BIO) has been found to 
alleviate different inflammatory diseases by positively regulating inflammatory 
cytokines(6,13,14,41–43).  Additionally, BIO has also been exhibited to promote 
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robust osteoblast differentiation, potent bone anabolism(9,40), natural tooth 
repair(15) and to prevent mandibular cartilage pathological changes(14).  Hence, 
BIO was proposed in this study to prevent periodontal disease progression 
because of its potency as an anti-inflammatory and an osteoinductive agent.  
However, in addition to its poor water solubility and lack of osteotropicity, 
oncogenic concerns(17), have limited BIO’s clinical applications. 
 
 
To overcome these limitations, we have developed a novel osteotropic hydrogel 
for local delivery of BIO with better water solubility and direct access to periodontal 
tissues and thus minimize potential long-term side effects associated with Wnt/β-
catenin signaling agonists(17,18).  In this study, the osteointegration or ionic 
bonding of Pluronic F127 hydrogel was improved through a straightforward two-
step reaction, optimizing this delivery system for bone regeneration(44).  The chain 
termini of Pluronic F127 were modified with pyrophosphate (PPi) without 
compromising gelation and viscous properties of F127.  In addition to the unique 
thermoresponsive characteristics of F127 hydrogel, this design was also built upon 
our previous studies in which Pluronic copolymers were modified with biomineral-
binding moiety (PPi) to develop dentotropic micelle formulations as an effective 
and safe delivery tool for antimicrobials to improve dental plaque prevention and 
treatment(45).  This novel thermoresponsive pyrophosphorolated hydrogel 
(PF127) should be capable of interacting with the periodontal hard tissues and 
achieving the ultimate goal of sustained local delivery to assist the clinical 
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management of periodontal disease. The findings of the present study validate this 
design objective and confirm the superior anti-inflammatory and periodontal bone 
preservation/regeneration capacity of the BIO loaded-PF127 hydrogel comparing 
to F127 hydrogel on experimental periodontitis rat model.  
The binding experiment (Fig. 9a) showed that pyrophosphorolated hydrogels have 
stronger binding to HA discs than F127 hydrogel, confirming that PF127 hydrogel 
is a viable strategy for drug delivery to hard tissues. Interestingly, BIO’s solubility 
in PF127 solution comparing to F127 was greatly improved and proportionally to 
the increase of the polymer concentration.  This observation could be explained 
partly by the better aqueous solubility of PF127 polymers as a function of the PPi 
content.  The cell viability data indicated that PF127 design retains the good 
biocompatibility of Pluronic F127 for 48 h(25) even after loading the drug.  
Similarly, it was shown that PF127 hydrogels with or without drug loading 
preserved the thermoresponsive properties of F127 hydrogels and were found to 
be dependent upon aqueous solubility of the polymer.  As the temperature 
increases, solubility decreases and thus micelle formation is promoted, leading to 
the tangling of micelles’ coronas and hence gel formation(46).  It is noted that the 
20% w/v PF127 exhibited low viscosity and formed weak hydrogel which might be 
due to the higher aqueous solubility of PF127 polymers, increasing the critical 
micellar concentration (CMC).   In vitro release of BIO through the PF127 
hydrogels and erosion profile was affected by the amount of polymer in the 
hydrogel.  The viscosity of the hydrogel increases as a function of polymer 
concentration which ultimately reduces the drug release rate, diffusion coefficient, 
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and surface erosion process, indicating that BIO release was mainly driven by a 
combination of diffusion and concurrent hydrogel erosion.  Though the relatively 
fast BIO release and gel erosion profile within 48 h might be disadvantageous for 
some applications where longer retention is desirable, its application for Wnt/β-
catenin agonists delivery may be advantageous as it may help to prevent sustained 
activation of Wnt/β-catenin signaling, which is associated with oncogenic activities 
(17,18).  Hence, PF127-BIO hydrogel seems to be an optimized and promising 
periodontal delivery system for such potent therapeutic agent (BIO) that would 
achieve the desired outcomes and avoid possible serious side effects associated 
with the inhibition of GSK3 and the overexpression of β-catenin.  Taken together, 
these in vitro data confirm that comparing to F127 hydrogel, PF127 hydrogel has 
stronger ionic bonding and interaction with bone-like materials as well as higher 
drug loading (solubility) with similar biocompatibility, rheological, release and gel 
erosion profiles. 
When evaluated in vivo using a ligature-induced periodontitis rat model, micro-CT 
analysis of alveolar bone showed that the PF127-BIO hydrogel treatment was the 
most effective treatment among all groups in preserving alveolar bone integrity 
(Fig. 11).  It prevented alveolar crest loss and maintained bone volume (BV) when 
compared to all other groups.  Also, in accordance with the micro-CT findings, the 
histological evaluation revealed superior osteogenic and anti-inflammatory effects 
of PF127-BIO hydrogel.  It significantly increased β-catenin positive cell score and 
reduced inflammatory cell score when compared to all other groups.  It also has a 
lower osteoclast score when compared to saline control (Fig. 12), suggesting 
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reduced erosion of the mineralized tissue within the periodontium.  These 
observations could be attributed to the osteogenic(9,40,47) and anti-inflammatory 
effects of BIO(2,13,42,43), respectively.  PF127 hydrogel itself did not show any 
significant protective effects against bone loss indicating that it did not contribute 
to preserving alveolar bone integrity.  As an important consideration for the effect 
Wnt/β-catenin agonists, they may be drained into the circulation after the local 
release.  Therefore, the femoral bone quality was analyzed to identify potential 
systemic osteogenic effects of BIO.  All treatment groups did not show any 
significant changes in the femoral bone quality when compared to control, 
suggesting that the effect of BIO was locally restricted to periodontal tissues.  In 
addition, we believe that the small localized doses of Wnt/β-catenin agonists used 
in animal studies are substantially lower than those used in clinical trials, indicative 
of a low potential to produce a systemic response(15)  
Overall, the weekly administration of PF127-BIO hydrogel was found to be more 
effective in preventing periodontitis-induced alveolar bone loss when compared to 
F127-BIO hydrogel and free BIO treatments.  We believe that after local 
administration, PF127-BIO hydrogel’s interaction with periodontal hard tissues 
enhances the retention of the hydrogel, thus ensuring the gradual release of BIO 
at the desired site.  This mechanism might provide a rational explanation of the 
superior therapeutic effect of PF127-BIO hydrogel than F127-BIO and dose 
equivalent free BIO in prevention of alveolar bone loss associated with 
periodontitis.  Clinically, local treatment for periodontal bone loss should be given 
when periodontitis lesions are identified.  Therefore, the treatment was initiated at 
116 
 
the time of ligature placement to make it more clinically relevant.  Furthermore, the 
weekly administration schedule would be easily adapted into current clinical dental 




In this study, we report the development and preparation of a novel osteotropic 
thermosensitive hydrogel delivery system by conjugating pyrophosphates (PPi) to 
the chain termini of Pluronic F127.  This hydrogel system not only enhanced drug 
loading but also exhibited affinity to hydroxyapatite (HA), with retained unique 
thermoresponsive properties of Pluronic F127.  When tested on an experimental 
periodontitis rat model, PF127-BIO hydrogel was found to be effective in 
preserving periodontium tissues and preventing disease progression.  As 
suggested by the results and upon further optimization, we believe this novel 
hydrogel as a local delivery system may have a great potential to be further 
























Figure 8.  Effect of different treatments on growth of MC3T3-E1 cells measured 
by CCK-8 assay following (a) 24 and (b) 48-hour exposure.  Data are shown as 












Figure 9. In vitro characterization of PF127 hydrogels. (a) Assessment of 
hydroxyapatite (HA) binding of 25% w/v PF127 hydrogels prepared with different 
ratios of F127-PPi and F127. **p< 0.01, and ****p<0.0001 when compared to F127 
hydrogel (ratio of 0); #p<0.05 and ##p< 0.01 when compared to ratio of 25 (one-
way ANOVA with Tukey’s multiple comparisons). (b) Saturated solubility of BIO in 
PF127 vs F127 solutions at 4 °C. **p< 0.01 and ****p<0.0001 (one-way ANOVA with 
Tukey’s multiple comparisons). (c) Cumulative BIO release from PF127 hydrogels 
at 37 °C.  (d) Erosion time of PF127 hydrogels incubated at 37 °C measured by 





Figure 10.  (a) Sol-gel-sol phase diagram for PF127 and PF127-BIO hydrogels. 
















   
Figure 11. The in vivo evaluation of PF127-BIO hydrogel efficacy in an 
experimental periodontitis rat model.  (a) Micro-CT sagittal images showing the 
effect of different treatments on the maxilla of cementoenamel junction (CEJ) to 
alveolar bone crest (ABC).  White vertical lines indicate ABC-CEJ distance. (b) 
Measurement of the linear distance between CEJ and ABC. (c-d) Quantitative 
analysis of alveolar bone quality after different treatments. Bone volume (BV), 
trabecular thickness (Tb.Th). Values are presented as the mean ± SD. *p<0.05, 






Figure 12.  Histological analysis of papillary connective tissue and alveolar bone 
between first molar (M1) and second molar (M2) after 3 weeks of different 
treatments.  (a-b) Representative images from different treatment groups of (a) 
H&E stained tissues and (b) IHC staining of β-catenin of connective tissue above 
the alveolar bone crest (ABC) and between first molar (M1) and second molar 
(M2). Scale bar = 100 μm. (c-e) Semi-quantitative assessment of (c) inflammatory 
cells, (d) osteoclasts, and (e) β-catenin positive cells interproximally between first 
molar (M1) and second molar (M2). Values are presented as the mean ± SD. *p< 
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Periodontal disease is a prevalent and chronic inflammatory disease that 
affects the supporting structures of the teeth including gingiva, periodontal 
ligament, and alveolar bone resulting in pocket formation, mobility, bone loss, and 
eventually may lead to tooth loss. In addition to direct bacterial degradation of 
periodontal tissue, the host immune response, which aims at protecting host 
tissues from bacterial aggression, also acts as a mediator of the periodontal 
damage(1). Current treatment strategies are aimed at reducing bacterial load by 
mechanical therapy and administration of antimicrobial agents(2,3). Additionally, 
host modulation agents have been utilized to ameliorate host response and reduce 
disease progression(4,5). However, these agents usually are given orally with 
large doses, causing antibiotic resistance, adverse drug reaction, and side effects, 
and subsequently reducing patient compliance(6,7). Additionally, oral drugs 
distribute to other organs of the body that may reduce drug concentration inside 
periodontal pocket(8). Alternatively, due to the nature of the local periodontal 
defect, local drug delivery in the form of intra-pocket administration prove to be 
more promising than oral administration(7,9). With local delivery strategies, a high 
concentration of drug inside the periodontal pocket can be attained with reduced 
systemic distribution, thereby minimizing side effects. However, rapid drug 
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clearance from the periodontal pocket requires repeated dosing which could 
reduce patient compliance.  
 
In Chapter 1, we have reviewed and discussed the local drug delivery 
systems that have been developed for periodontal disease. These local systems 
have been successful and shown positive outcomes in many clinical studies in 
terms of overall periodontal health. However, most of the currently available 
formulations, which focused only on delivering anti-microbial agents, suffer from 
several limitations including lack of interaction or bonding with periodontal tissues, 
need for removal of non-biodegradable delivery systems, lack of penetration into 
deeper regions of periodontal pocket and poor patient compliance, indicative of a 
low clinical translation potential and also highlighting the urgent need for the 
development of effective drug delivery systems that can preserve periodontal 
tissues. 
 
In Chapter 2, we developed a novel osteotropic simvastatin (SIM) prodrug 
by conjugating SIM trimer to a pyrophosphate (PPi). This prodrug design has 
enhanced SIM’s solubility and exhibited strong affinity to hydroxyapatite (HA). 
Also, this prodrug retained bone anabolic and anti-inflammatory properties of SIM. 
When tested on an experimental periodontitis rat model, SIM-PPi was found to be 
more effective than free SIM in ameliorating inflammation and preserving 





In Chapter 3, in an attempt to avoid the complexity of chemical syntheses, 
we reported and discussed another strategy of local drug delivery for periodontal 
disease. A novel osteotropic thermosensitive hydrogel delivery system was 
developed, utilizing unique properties of Pluronic F127. Pyrophosphates (PPi) 
were conjugated to the chain termini of Pluronic F127. This hydrogel system 
(PF127) not only enhanced drug loading but also exhibited affinity to 
hydroxyapatite (HA), with retained unique properties of Pluronic F127. A GSK3 
inhibitor (BIO) was used as a drug model that has anti-inflammatory and 
osteogenic effects. When tested on an experimental periodontitis rat model, 
PF127-BIO hydrogel was found to be effective in preserving periodontium and 
preventing disease progression.  
 
In conclusion, these two novel delivery strategies (SIM-PPi prodrug and 
PF127 hydrogel) were shown to address some of the limitations associated with 
current local delivery systems for periodontal disease, indicating that they may 











1. Evaluate the therapeutic efficacy on diabetic background, as the risk of 
periodontal disease is increased by approximately threefold in diabetic 
individuals compared with non-diabetic individuals.  
2. Smoking is another major risk factor associated with the severity of 
periodontitis. Hence, establishing a successful animal model would be of 
great interest.   
3. Several natural products have been identified and studied in the treatment 
of periodontal disease. PF127 hydrogel could be utilized to address their 














1.  Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 
[Internet]. 2005 Nov 19 [cited 2017 Nov 6];366(9499):1809–20. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/16298220 
2.  Herrera D, Sanz M, Jepsen S, Needleman I, Roldán S. A systematic 
review on the effect of systemic antimicrobials as an adjunct to scaling and 
root planing in periodontitis patients. J Clin Periodontol [Internet]. 2002 
[cited 2017 Aug 23];29 Suppl 3:136-59; discussion 160-2. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12787214 
3.  Greenstein G. Local drug delivery in the treatment of periodontal diseases: 
assessing the clinical significance of the results. J Periodontol [Internet]. 
2006 Apr [cited 2017 Aug 23];77(4):565–78. Available from: 
http://www.joponline.org/doi/10.1902/jop.2006.050140 
4.  Williams RC, Jeffcoat MK, Howell TH, Reddy MS, Johnson HG, Hall CM, et 
al. Ibuprofen: An inhibitor of alveolar bone resorption in beagles. J 
Periodontal Res [Internet]. Blackwell Publishing Ltd; 1988 Jul 1 [cited 2017 
Aug 23];23(4):225–9. Available from: http://doi.wiley.com/10.1111/j.1600-
0765.1988.tb01363.x 
5.  Raja S, Byakod G, Pudakalkatti P. Growth factors in periodontal 
regeneration. Int J Dent Hyg [Internet]. 2009 May [cited 2017 Aug 




6.  Walker CB. Selected antimicrobial agents: Mechanisms of action, side 
effects and drug interactions. Periodontol 2000. 1996;  
7.  Southard GL, Godowski KC. Subgingival controlled release of antimicrobial 
agents in the treatment of periodontal disease. Int J Antimicrob Agents. 
1998;  
8.  Goodson JM. Antimicrobial strategies for treatment of periodontal 
diseases. Periodontol 2000. 1994;  
9.  Schwach-Abdellaoui K, Vivien-Castioni N, Gurny R. Local delivery of 
antimicrobial agents for the treatment of periodontal diseases. European 
Journal of Pharmaceutics and Biopharmaceutics. 2000.  
 
